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Abstract 
 
Machado-Joseph disease (MJD), the most common form of autosomal 
dominantly-inherited ataxia, belongs to a group of neurodegenerative disorders sharing 
the attribute of being caused by unstable expansions of CAG codon repeats in the 
respective genes. These disorders are collectively named as polyglutamine (polyQ) 
expansion diseases, since that expansion is translated as a lengthy glutamine 
sequence in the otherwise unrelated proteins encoded by each gene. Ataxin-3 (atx3), 
the protein associated with MJD, is a deubiquitinating enzyme (DUB) which mainly 
comprises a N-terminal catalytic domain, termed Josephin domain (JD), and a C-
terminal tail that contains two or three ubiquitin-interacting motifs (UIMs) and the polyQ 
stretch. Though its concrete biological function remains to be elucidated, information 
regarding atx3 activity and molecular interactions points out some involvement with the 
ubiquitin-proteasome pathway (UPP) and with transcription regulation. To this date, the 
experimentally observed deubiquitinating activity has been reported as being very low, 
being admitted that, as with many other DUBs, atx3 activity may be closely regulated 
and thus require external factors to reach optimal levels. 
The way expanded atx3 and every other polyQ-expanded proteins lead to the 
corresponding diseases also remains to be determined but, though it is admitted that 
there are some events common to all of the diseases (including formation of toxic 
protein aggregates), the different properties of each particular protein hosting the polyQ 
expansion are probably the cause of the different profiles exhibited by each polyQ 
expansion disease. One way by which this protein context may play a role in these 
neurodegenerative diseases is related to the differential susceptibility to be targeted by 
post-translational modifications (PTMs), a group of ubiquitous and frequently reversible 
mechanisms that regulate many protein properties, modulating their function, 
subcellular localization and interactions. Importantly, cell-specific differences in protein 
properties resulting from differential regulation by PTMs may explain the region-specific 
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degeneration observed in every polyQ expansion disease. Many PTMs targeting polyQ 
expansion proteins have been related with the regulation of some of their properties 
and sometimes seen as interfering with events involved in disease development. In the 
particular case of atx3, PTMs also constitute a promising mechanism for regulation of 
its deubiquitinating activity. Consequently, the goal of the current work was to identify 
novel PTMs of atx3. 
We chose to focus our attention on phosphorylation and sumoylation, two PTMs 
that have been associated with regulation of both DUBs and polyQ expansion proteins. 
In order to identify new phosphorylation sites in atx3, we immunoprecipitated an atx3 
fusion protein from transfected HEK 293FT cells and analyzed it recurring to a mass 
spectrometric strategy specially directed at the mapping of phosphorylation sites. This 
analysis determined for the first time that serine 12 of atx3 is phosphorylated. Usage of 
no artificial stimulus other than that of the phosphatase inhibitor okadaic acid (OA) 
prompts us to admit that this modification occurs normally in HEK 293FT cells. After 
analyzing the tertiary structure of the JD and observing the proximity of this amino acid 
to those of the active site of the protein, we speculate that this modification likely 
influences atx3 deubiquitinating activity. As for sumoylation, we submitted 6His-tagged 
JD purified from E. coli to an in vitro sumoylation assay and concluded that it 
conjugated with small ubiquitin-like modifier 2 (SUMO2). Though we were unable to 
confirm this result in vivo, it constitutes the first evidence for sumoylation of atx3 and 
indicates that the catalytic domain of the protein is a target for this modification. 
Further study of the PTMs we identified and subsequent characterization of the 
way they regulate atx3 properties may help us increase our knowledge about atx3 
function and the mechanisms responsible for MJD development. 
 
Keywords: Machado-Joseph disease, polyglutamine expansion diseases, ataxin-3, 
Josephin domain, deubiquitinating enzymes, phosphorylation, sumoylation 
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Resumo 
 
A doença de Machado-Joseph (MJD), a ataxia com hereditariedade 
autossómica dominante mais comum, pertence a um grupo de doenças 
neurodegenerativas que partilham o facto de serem causadas por expansões instáveis 
de repetições de codões CAG nos genes correspondentes. Estas desordens são 
colectivamente designadas doenças de poliglutaminas (polyQ), uma vez que a 
expansão é traduzida como uma sequência expandida de glutaminas nas proteínas 
codificadas por cada gene; essas proteínas não estão, de outro modo, relacionadas. A 
ataxina-3 (atx3), a proteína associada à MJD, é uma enzima com actividade de 
hidrolase de ubiquitinas (DUB) formada por um domínio catalítico presente no terminal 
amino, designado de domínio Josephin (JD), e por uma cauda presente no terminal 
carboxílico, que contém dois ou três motivos de interacção com ubiquitina (UIMs) e a 
sequência de polyQ. Embora a função fisiológica desta proteína permaneça ainda 
desconhecida, as informações existentes acerca da actividade da atx3 e das 
interacções moleculares que estabelece indiciam um certo envolvimento com a via da 
ubiquitina-proteossoma (UPP) e com a regulação da transcrição. Até à data, a 
actividade proteolítica detectada experimentalmente tem sido considerada muito baixa, 
admitindo-se que, tal como acontece com muitas outras DUBs, a actividade da atx3 
deverá ser estritamente regulada e necessitará, portanto, de factores externos para 
atingir níveis fisiologicamente significativos. 
A forma como a atx3 expandida e todas as outras proteínas com uma 
expansão de polyQ conduzem às doenças em questão também não foi ainda 
determinada, mas, embora se admita que certos acontecimentos são comuns a todas 
as patologias (incluindo a formação de agregados tóxicos de proteínas), reconhece-se 
que as diferentes propriedades de cada proteína que contém a expansão de polyQ 
são a causa dos diferentes perfis apresentados por cada doença de polyQ. Um modo 
através do qual este contexto proteico pode ser importante relaciona-se com a 
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diferente susceptibilidade para ser alvo de modificações pós-traducionais (PTMs), um 
grupo de mecanismos ubíquos e frequentemente reversíveis que regulam muitas 
propriedades das proteínas, modulando a sua função, a sua localização subcelular e 
as suas interacções. Um aspecto a ter em conta é a eventual possibilidade de se vir a 
explicar a degeneração específica de determinadas regiões do sistema nervoso que 
se observa em todas as doenças de expansão de polyQ como resultado de diferenças 
nas propriedades das proteínas que resultem de uma regulação diferencial por PTMs. 
Muitas PTMs de proteínas com expansão de polyQ têm sido relacionadas com 
algumas das suas propriedades e, por vezes, admitidas como interferindo em 
processos relacionados com o desenvolvimento das patologias. No caso particular da 
atx3, as PTMs poderão também constituir um mecanismo promissor de regulação da 
sua actividade de hidrolase de ubiquitina. Consequentemente, o objectivo deste 
trabalho era identificar novas PTMs da atx3. 
Escolhemos concentrar a nossa atenção na fosforilação e na sumoilação, duas 
PTMs que têm sido associadas tanto com a regulação das DUBs como das proteínas 
com expansão de polyQ. De modo a identificar novos locais de fosforilação da atx3, 
imunoprecipitámos uma proteína de fusão da atx3 a partir de células HEK 293FT e 
analisámos a amostra recorrendo a um método de espectrometria de massa 
especialmente direccionado para o mapeamento de locais de fosforilação. Esta análise 
determinou pela primeira vez que a serina 12 da atx3 é fosforilada. O facto de não ter 
sido usado nenhum estímulo artificial à excepção do ácido okadaico, um inibidor de 
fosfatases, leva-nos a admitir que esta modificação ocorre normalmente em células 
HEK 293FT. A análise da estrutura terciária do JD e consequente observação da 
proximidade entre este aminoácido e os aminoácidos do local activo da proteína leva-
nos a especular que é provável que esta modificação influencie a actividade 
proteolítica da atx3. No que diz respeito à sumoilação, submetemos 6His-JD purificado 
a partir de E. coli a um ensaio de sumoilação in vitro e concluímos que ele se 
conjugava com SUMO2. Embora não tenha sido possível confirmar este resultado in 
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vivo, esta é a primeira prova de sumoilação da atx3 e indica que o domínio catalítico 
da proteína é alvo desta modificação. 
A continuação do estudo das PTMs que identificámos e subsequente 
caracterização do modo como regulam as propriedades da atx3 poderão ajudar-nos a 
compreender melhor a função da atx3 e os mecanismos responsáveis pela MJD. 
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1.1 – Machado-Joseph disease 
 
1.1.1 – Machado-Joseph disease presentation, neurological features and 
genetics 
 
 Machado-Joseph disease (MJD), otherwise known as spinocerebellar ataxia 
type 3 (SCA3), is an inherited neurodegenerative disorder originally described in 
people of Portuguese Azorean descent (Rosenberg, 1992; Sudarsky & Coutinho, 
1995), but nowadays admitted as the most common form of autosomal dominantly-
inherited ataxia in the world (Ranum et al., 1995; Riess et al., 2008; Schöls et al., 
2004). So far, apart from Portugal, the disease has been identified in Spain, Italy, 
Germany, China, Taiwan, Japan, Australia, Brazil, United States and Canada 
(Rosenberg, 1992; Riess et al., 2008; Sudarsky & Coutinho, 1995). 
MJD neurodegeneration profile involves neuronal loss in selective regions of the 
nervous system, including the cerebellum (spinocerebellar pathways and dentate 
nucleus), the substantia nigra, nuclei from the pons, spinal cord and cranial nerves 
(including locus coeruleus and vestibular nuclei), as well as visual, auditory, vestibular, 
somatosensory and ingestion-related systems; cerebral and cerebellar cortexes, 
inferior olive and Purkinje cells are moderately preserved (Dürr et al., 1996; Maciel et 
al., 1995; Rosenberg, 1992; Rüb et al., 2008; Sudarsky & Coutinho, 1995). Regarding 
brain functionality, metabolism (assessed by glucose utilization) was shown to 
decrease in the cerebellum, brainstem, cerebral cortex, thalamus and putamen (Riess 
et al. 2008; Soong et al., 1997; Wüllner et al., 2005), and both dopaminergic and 
cholinergic neurotransmissions were reported to be negatively affected (Rüb et al., 
2008; Wüllner et al., 2005; Yen et al., 2000). MJD pathogenesis results in a set of 
characteristic clinical symptoms, including the hallmark progressive ataxia, other 
general neuromuscular complications like dystonia, dysarthria, spasticity, rigidity, 
fasciculations, postural instability and proprioceptive loss, visual (nystagmus, eyelid 
Introduction 
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retraction, ophthalmoparesis, double vision) and speech (dysarthria) disorders, 
dysphagia, amyotrophy, corticospinal and autonomic nervous system dysfunctions and 
neuropathy (Riess et al., 2008; Rosenberg, 1992; Soong et al., 1997; Sudarsky & 
Coutinho, 1995). 
The gene causatively associated with MJD is termed MJD1 (SCA3) and is 
located on the long arm of chromosome 14 (14q32.1) (Kawaguchi et al., 1994; 
Takiyama et al., 1993). The disease develops in people carrying an unstable expansion 
of CAG repeats, which encode for glutamines, in the coding region of that gene’s 
sequence. This results in an expanded tract of repeated glutamines in the protein 
encoded by MJD1, named ataxin-3 (atx3) (Kawaguchi et al., 1994). In the healthy 
population, the number of CAG repeats lies between 10 and 51, with 55 to 87 CAG 
repeats being reported to associate with the disease (Cummings & Zoghbi, 2000; 
Maciel et al., 2001).  Nonetheless, CAG repeat numbers between 45 and 51 seem to 
belong to an overlapping region of healthy and disease phenotypes, since, while the 
longest repeat number detected in healthy people was 51, some smaller repeats have 
also been identified as associated with the development of MJD, the smallest of then 
being 45 CAG repeats (Maciel et al., 2001; Riess et al., 2008). 
 
1.1.2 – Polyglutamine expansion diseases 
 
In accordance to what has been said above, MJD belongs to a wider group of 
neurodegenerative disorders, the polyglutamine (polyQ) expansion diseases, defined 
by the fact that they all result from the same kind of polyQ expansion of their 
associated proteins. This group also includes Huntington’s disease (HD), 
dentatorubral-pallidoluysian atrophy (DRPLA), spinal and bulbar muscular atrophy 
(SBMA) and spinocerebellar ataxia types (SCA) 1, 2, 6, 7 and 17 (Gatchel & Zoghbi, 
2005; Zoghbi & Orr, 2000) (Table I). All these diseases are characterized by a selective 
neuronal loss accompanied by a collection of associated physical and psychological 
Introduction 
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complications, though the particular features vary among the different diseases 
(Gatchel & Zoghbi, 2005). In fact, although the different polyQ diseases have several 
common traits, the proteins responsible for each of them share no homology outside 
the polyQ tract, being unrelated and having very different biological functions (Gatchel 
& Zoghbi, 2005; Zoghbi & Orr, 2000).  
 
Table I: Biologic features of polyQ expansion diseases (adapted from 
Gatchel & Zoghbi, 2005 and Shao & Diamond, 2007) 
Disease 
name 
Mutated 
gene 
Protein 
product 
Putative 
function 
CAG repeat size Regions most 
affected Normal Pathogenic 
HD HD huntingtin 
Signalling, 
transport, 
transcription 
6-34 36-121 Striatum, cerebral cortex 
DRLPA DRPLA atrophin 1 Transcription 7-34 49-88 
Cerebellum, cerebral 
cortex, basal ganglia, 
Luys body 
SBMA AR androgen receptor 
Steroid-hormone 
receptor 9-36 38-62 
Anterior horn and 
bulbar neurons, 
dorsal root ganglia 
SCA1 SCA1 ataxin-1 Transcription 6-39 40-82 
Cerebellar Purkinje 
cells, dentate 
nucleus, brainstem 
SCA2 SCA2 ataxin-2 RNA metabolism 15-24 32-200 
Cerebellar Purkinje 
cells, brainstem, 
frontotemporal lobes 
SCA3 MJD/SCA3 ataxin-3 
Deubiquitinating 
activity and 
transcription 
regulation 
10-51 55-87 
Cerebellar dentate 
neurons, basal 
ganglia, brainstem, 
spinal cord 
SCA6 CACNA1A CACNA1A 
P/Q-type α1A 
calcium channel 
subunit 
4-20 20-29 
Cerebellar Purkinje 
cells, dentate 
nucleus, inferior olive 
SCA7 SCA7 ataxin-7 Transcription 4-35 37-306 
Cerebellum, 
brainstem, macula, 
visual cortex 
SCA17 SCA17 TBP Transcription 25-42 47-63 Cerebellar Purkinje cells, inferior olive 
 
Abbreviations: HD, Huntington’s disease; DRPLA, dentatorubral-pallidoluysian atrophy; SBMA, spinal and bulbar 
muscular atrophy; SCA, spinocerebellar ataxia; MJD, Machado-Joseph disease; CACNA1A, calcium channel, voltage 
dependent, P/Q type, α1A subunit; TBP, TATA box binding protein. 
 
The mechanisms by which the expanded proteins lead to the stated pathologies 
are still not completely understood. One important common aspect to all polyQ 
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expansion diseases is the existence of a negative correlation between the age of onset 
and the number of CAG repeats, meaning that a greater number of such repeats 
results in an earlier development of the corresponding disease (Dürr et al., 1996; 
Maciel et al., 1995; Ranum et al., 1995; Riess et al., 2008; Zoghbi & Orr, 2000). 
Additionally, different repeat numbers have been associated with different clinical 
presentations; in the particular case of MJD, four subphenotypes have been defined 
according to the age of onset and the particular symptomatic profiles (Dürr et al., 1996; 
Maciel et al., 1995; Riess et al., 2008; Rosenberg, 1992). The facts that the polyQ 
expansion is a common causative aspect to all these diseases and that its size 
correlates negatively with the age of onset are indicative of the importance the 
expanded polyQ sequence has on the mechanisms leading to the diseases. The 
involvement of the polyQ expanded tracts has been explained in several ways, 
including: a) polyQ stretch-induced modifications of the host protein function; b) 
generation of toxic polyQ-containing fragments after auto-cleavage of the host protein; 
c) polyQ tract-induced conformational changes in the protein, leading to an 
aggregation-prone state and consequent generation of toxic oligomers; d) 
transcriptional changes, caused by interactions of the expanded protein with specific 
transcription factors; e) proteotoxic stress as a result of the disruption of the quality-
control systems of the cell; f) mitochondrial dysfunction (Shao and Diamond, 2007). 
One characteristic hallmark of all polyQ expansion diseases is the formation of large 
macromolecular protein aggregates or inclusion bodies containing the expanded and 
misfolded disease protein, in the nucleus and/or cytoplasm of neurons (and glial cells, 
in rare cases) (Zoghbi & Orr, 2000). These cell-generated structures, distinct from the 
small aggregates or oligomers formed by the self-association of the proteins, have 
been related to the pathogenesis of the polyQ expansion diseases for a long time, but 
recently many authors have been supporting the idea that they actually result from end-
stage protective cellular mechanisms moved against the toxicity of the misfolded 
expanded protein (Arrasate et al., 2004; Ross & Poirier, 2004; Slow et al., 2005, Shao 
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& Diamond, 2007). Notably, polyQ toxicity has been associated not only with the 
expanded proteins that are translated from the CAG-expanded genes, but also with the 
expanded CAG repeat-containing RNA, which has been shown to cause toxicity by 
itself (Li et al., 2008). 
Although there are some common aspects to the different polyQ diseases that 
can be attended to in order to study possible common pathogenesis mechanisms, 
there are particular aspects to them as well. The different neurodegeneration and 
symptomatic profiles of each polyQ expansion disease may be explained as a result of 
the fact that the polyQ expansion is inserted into a different host protein in each 
different disease. The diverse properties of each of those proteins, which include their 
subcellular localization, abundance, activity and biological role, along with the way the 
polyQ expansion affects them, shall constitute the factors responsible for each 
disease’s specificity (Gatchel & Zoghbi, 2005). The cellular mechanisms proposed to 
link atx3 polyQ expansion with MJD pathogenesis will be discussed in later sections. 
 
1.2 – Ataxin-3 
 
1.2.1 – Distribution and ubiquity  
 
Atx3 is a protein of wide distribution among the different eukaryotic groups of 
living organisms, having been identified in protozoans, plants, fungi and animals, from 
nematodes to arthropods and vertebrates (National Center for Biotechnology 
Information - NCBI - protein database). In mice and humans, despite the localized 
neuronal degeneration observed in MJD patients, atx3 displays an ubiquitous 
expression among different body tissues and cell types (do Carmo Costa et al., 2004; 
Ichikawa et al., 2001; Paulson et al., 1997a; Schmidt et al., 1998; Trottier et al., 1998). 
It was found to be widely expressed throughout the brain, though different regions 
present varying expression levels (Trottier et al., 1998). 
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1.2.2 – Structure and domains 
 
Atx3 is a protein essentially composed of a structured globular N-terminal 
domain, followed by a flexible C-terminal tail (Masino et al., 2003). The N-terminal 
domain, termed Josephin domain (JD), shows ubiquitin (Ub) protease activity, while the 
flexible tail presents two ubiquitin-interacting motifs (UIMs), followed by the variable 
length polyQ region, whose expansion beyond a certain threshold is responsible for 
MJD (Albrecht et al., 2004; Burnett et al., 2003; Nicastro et al., 2005) (Figure 1). 
Four different isoforms probably resulting from alternative splicing have been 
extensively described, the longest having an approximate molecular weight of 42 kDa 
(Goto et al., 1997; Ichikawa et al., 2001; Trottier et al., 1998). Notably, one of these 
isoforms has an extra UIM localized in the C-terminal, downstream the polyQ domain. 
Interestingly though, a recent study identified a total of 56 human alternative splicing 
variants, expected to be translated into at least 20 isoforms, with varying predicted 
domain arquitecture (Bettencourt et al., 2009).  
 
 
 
 
 
Figure 1 – Schematic illustration of atx3 domain structure. The N-
terminal catalytic JD is followed by two UIMs that precede the polyQ region, 
of variable length (Qn
 
). One isoform has a third UIM at the C-terminal, 
downstream the polyQ tract.  
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1.2.3 – Function and biological role 
 
1.2.3.1 – Ubiquitin binding and deubiquitinating activity: involvement with 
the ubiquitin-proteosome pathway 
 
Despite the existent information about the domains and activity of atx3, the 
protein’s concrete biological function and physiological role remain to be elucidated. 
There are, however, several clues that suggest an involvement with the ubiquitin-
proteasome pathway (UPP), the main mechanism for the turnover of short-lived or 
damaged proteins (Doss-Pepe et al., 2003). 
Ubiquitination, i e, the covalent attachment of a Ub molecule or a polyUb chain 
to one or several lysine residues of a target protein, constitutes a mechanism 
regulating many different cellular activities, including protein degradation through the 
well-known UPP, DNA repair, chromatin remodeling, cell cycle progression, subcellular 
localization and signaling pathways (Reyes-Turcu et al., 2009; Reyes-Turcu & 
Wilkinson et al., 2009; Weisman et al., 2001). Importantly, polyUb chains can have 
diverse topologies resulting from different linkage modes existing between Ub 
monomers, and the different Ub arrangements produced by different types of Ub 
attachment determine the way the target protein properties are regulated (Reyes-Turcu 
& Wilkinson et al., 2009; Weisman et al., 2001; Winborn et al., 2008). Atx3 is able to 
bind polyUb chains through the UIMs located at the C-terminal region, interacting with 
both lysine 48 and lysine 63-linked chains in a UIM-dependent manner, in vitro 
(Winborn et al. 2008). There is, however, a preference for chains of no less than four 
Ub monomers and, coincidently, lysine 48-linked polyUb chains of four or more 
monomers are the ones involved in the targeting of proteins for proteasomal 
degradation (Burnett et al., 2003; Mao et al., 2005; Schmitt et al., 2007). Atx3 has also 
been shown to be able to bind polyubiquitinated proteins in neural cells in a UIM-
dependent way (Berke et al. 2005). 
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Furthermore, as previously mentioned, the JD shows Ub protease activity, 
being capable of promoting the cleavage of isopeptide bonds existing between Ub 
monomers. This was first predicted through an integrative bioinformatic analysis of atx3 
sequence (Scheel et al., 2003) and later confirmed by biochemical experimentation 
using model substrates and by seeing that Ub-aldehyde, a specific Ub protease 
inhibitor, decreases atx3 activity (Burnett et al., 2003). Such activity established atx3 
and other identified JD-containing proteins as deubiquitinating enzymes (DUBs) 
(Burnett et al., 2003; Scheel et al., 2003). 
In cells, DUBs are a group of enzymes responsible for removing Ub or polyUb 
chains from a target protein, processing Ub preproteins and remodeling or 
disassembling bound or unbound polyUb chains, this way participating in the regulatory 
mechanisms that utilize ubiquitination signals (Reyes-Turcu et al., 2009; Reyes-Turcu 
& Wilkinson, 2009). There are five families of DUBs encoded by the eukaryotic 
genomes (one of which is constituted by atx3 and the other JD-containing proteins), 
and, despite lacking a great sequence or structural similarity, the catalytic cores and 
active site residues of four of them closely resemble the classical cysteine protease 
papain (Ha & Kim, 2008; Reyes-Turcu, 2009; Reyes-Turcu & Wilkinson, 2009). 
According to its tertiary structure, the JD of atx3 is mainly composed of two 
subdomains - a globular catalytic subdomain and a helical hairpin - with the catalytic 
site being located in the cleft that exists between them (Mao et al., 2005; Nicastro et 
al., 2005). Structural comparison between the JD and papain-like cysteine proteases 
shows that the JD shares great structural similarity with many members of this enzyme 
group, even greater than with other DUBs (Figure 2). Nonetheless, the amino acids of 
the catalytic triad, cysteine 14, histidine 119  and asparagine 134, show homology with 
the ones present in the Ub C-terminal hydrolases (UCH) and Ub-specific processing 
proteases (USP) families of DUBs (Mao et al., 2005; Nicastro et al., 2005; Scheel et al., 
2003). As is common for DUBs and papain-like cysteine proteases in general, the 
active site cysteine is located on a α-helix, while the histidine is located on a β-strand.  
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Figure 2 – Atx3 JD shares structural similarity with papain-like cystein 
proteases. Comparison between the atx3 JD structure (Protein Data Bank – 
PDB – ID code 1YZB) and those of the cystein proteases staphopain (PDB 
ID code 1CV8), avirulence protein (PDB ID code 1UKF), papain (PDB ID 
code 1PE6), yeast Ub C-terminal hidrolase 1 (YUH1; PDB ID code 1CMX) 
and Ub C-terminal esterase L3 (UCH-L3; PDB ID code 1UCH). YUH1 and 
UCH-L3 are both DUBs. The side chains of the catalytic triad are shown on 
each structure as sticks. (Adapted from Nicastro et al., 2005) 
 
The precise physiological role of most DUBs remains undetermined, though, 
considering there is a great number of DUBs and a great variety in Ub and polyUb 
attachment arrangements, it is believed that different enzymes specifically recognize 
different kinds of ubiquitination signals. In the case of atx3, inhibition of the catalytic 
activity results in the increase of polyubiquitinated proteins (localized primarily in the 
nucleus), in a degree similar to what is observed when the proteasome is inhibited 
(Berke et al. 2005). This supports the idea of atx3 involvement with the 
polyubiquitinated proteins targeted for proteasomal degradation. 
 Results suggest that atx3 functions as a polyUb-editing protease, shortening 
polyUb chains, rather than favoring complete disassembly of polyUb chains, in order to 
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yield free Ub (Burnett et al., 2003; Burnett & Pittman, 2005; Winborn et al., 2008). UIMs 
may help to recruit the polyubiquitinated substrates and position the substrates 
relatively to the catalytic site in a way that allows for a sequential editing (Mao et al., 
2005; Winborn et al., 2008). In fact, many DUBs have non-catalytical domains that 
contribute to recognition of different chain linkages (Reyes-Turcu & Wilkinson, 2009). 
The increase of polyubiquitinated proteins observed when atx3 catalytic activity is 
inhibited occurs only when the UIMs are intact, suggesting that they are important in 
the presentation of substrates to the JD (Berke et al. 2005). Importantly, Burnett and 
Pittman (2005) reported that atx3 is able to edit lysine 48-linked polyUb chains from a 
polyubiquitinated model protein (125
However, these considerations remain limited, taking into account that they are 
based only on in vitro observations. Importantly, to this date, atx3 steady state kinetic 
parameters have not been determined, though the proteolytic cleavage observed in 
vitro is very slow (Chow et al., 2004b; Winborn et al., 2008). This suggests that there 
must be some kind of external factor(s) required for optimal proteolysis (Chow et al., 
2004b; Reyes-Turcu & Wilkinson, 2009). Moreover, as for many DUBs, the actual 
substrate(s) targeted by atx3 in the physiological context remains elusive, thus limiting 
our understanding of its function (Reyes-Turcu & Wilkinson, 2009). The low activity 
observed for atx3 may also be explained by the absence of the proper substrate, since 
the majority of DUBs has a suboptimal activity, determining that association with the 
I-lysozyme) in vitro, at the same time blocking its 
proteasome-dependent degradation. Therefore, It has been proposed that atx3 partially 
deubiquitinates proteins and prevents their degradation by binding through the UIMs, 
while possibly maintaining their degradation signals. Nonetheless, Winborn et al. 
(2008) observed that atx3 preferentially cleaves lysine 63-linked chains and chains of 
mixed lysine 48 and lysine 63 linkage, suggesting that atx3 may function as a regulator 
of topologically complex polyUb chains. UIMs are important in determining this 
specificity, again supporting the idea that they may be important in positioning the 
polyUb chains for proteolytic cleavage (Winborn et al., 2008). 
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substrate(s) is required for a transition into an optimal catalytic-competent conformation 
(Reyes-Turcu et al., 2009). 
The first in vivo clues to atx3 function as a DUB come from studies involving 
atx3 knockout (KO) mice (Schmitt et al., 2007). When compared to wild-type animals, 
atx3 KO mice showed no significant differences in terms of viability, fertility, health, 
emotionality and sensory or motor functions, nor have they revealed any morphological 
abnormalities. Noteworthy, however, is the observation that atx3 KO mice had 
increased levels of ubiquitinated proteins, a fact that substantiates atx3 role as a DUB 
in vivo. The absence of deleterious physiological consequences was suggested to be 
due to redundancy existing among DUBs (Schmitt et al., 2007). 
Taken together, these results show that atx3 acts as a DUB likely associated 
with the UPP, though its precise biological role remains unclear. Nevertheless, the 
deubiquitinating activity may be important in a variety of other cellular processes, taking 
into account that ubiquitination, in all its alternative linkage forms, serves many different 
cellular functions, other than targeting proteins for proteasomal degradation (Todi, et 
al., 2007; Winborn et al., 2008). For instance, lysine 63-linked polyUb chains, shown to 
be bound and edited by atx3, serve functions in DNA repair mechanisms, translation, 
endocytosis and transport (Weissman, 2001; Winborn et al., 2008). The polyQ 
expansion of pathogenic atx3 may alter or block its function, and such incident may be 
relevant for the disease mechanisms of MJD. 
 
1.2.3.2 – Ataxin-3 interactors and possible related functions 
 
Several atx3 interacting partners have been identified so far, and the 
understanding of such interactions may provide clues into atx3 function. 
Atx3 has been shown to interact with p97/valosin-containing protein (VCP) 
trough the C-terminal region  (Boeddrich et al., 2006; Hirabayashi et al., 2001; Mao et 
al., 2005; Matsumoto et al., 2004; Zhong & Pittman, 2006) and with two human 
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homologs of the yeast DNA repair protein Rad23, HHR23A and HHR23B, through the 
JD (by the face opposite to the catalytic site) (Ferro et al., 2007; Nicastro et al., 2005; 
Wang et al., 2000). Both p97/VCP and HHR23A and B have been implicated in many 
different biological processes, including the UPP; they have both been linked to the 
shuttling of polyubiquitinated substrates to the proteasome for degradation and in 
particular to the endoplasmic reticulum-associated degradation (ERAD), i e, the system 
that mediates the ubiquitination of misfolded proteins or unassembled complex 
constituents present in the secretory pathway and their exportation to the cytosol for 
degradation by the proteasome (Albrecht et al., 2004; Burnett et al., 2003; Doss-Pepe 
et al., 2003; Wang et al., 2004; Wang et al., 2006). Atx3 interaction with these proteins 
further suggests its involvement in the UPP (Burnett et al., 2003; Mao et al., 2005), 
and, in effect, atx3 has been associated with the ERAD, though not with much 
consensus: there is dispute regarding whether atx3 promotes or decreases 
degradation by this pathway (Wang et al., 2006; Zhong & Pittman, 2006). Atx3 has 
even been found to associate with the proteasome itself through its N-terminal (Doss-
Pepe et al., 2003), but a recent study showed that the interaction between them is not 
very strong or even direct (Todi et al., 2007). Functioning in articulation with these 
interactors, atx3 may act in a number of different ways, a) trimming polyUb chains of a 
substrate, thus facilitating the subsequent disassembly of the chain by proteasome-
associated DUBs, b) editing polyUb chains in order to guarantee that the substrate is 
correctly targeted for degradation, or c) functioning as a transiently associated subunit 
of the proteasome and recognizing some of its substrates (Broeddrich et al., 2006; 
Wang et al., 2008). 
Atx3 has also been shown to interact with neural precursor cell expressed 
developmentally downregulated gene 8 (NEDD8), a Ub-like protein, reportedly in a 
substrate-like manner (Ferro et al., 2007; Mori et al., 2005). NEDD8 can be conjugated 
with other proteins in a way reminiscent of ubiquitination and such attachment, referred 
to as neddylation, has been reported to regulate target protein’s function. The 
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interaction between atx3 and NEDD8, along with a possibly observed deneddylase 
activity of atx3, may interfere with the neddylation of other substrates and thus 
influence the processes where attachment of NEDD8 is involved (Ferro et al., 2007).  
Aggresomes are misfolded protein aggregates that are formed near the 
microtubule-organizing center (MTOC) when the proteasome isn’t able to deal with 
misfolded proteins. These structures seem to be of physiologic importance, since those 
defective proteins are then degraded by lysosomes, contributing to the cellular 
homeostasis (Markossian & Kurganov, 2004). Endogenous atx3 seems to play a role in 
the regulation of aggresome formation, having been shown to co-localize with 
aggresome and preaggresome particles and to be important in the formation of the 
aggresomes themselves (Burnett & Pittman, 2005). Atx3 also associates with dynein 
and histone deacetylase 6 (HDAC6), both constituents of the complex responsible for 
the transport of misfolded proteins to the MTOC (Burnett & Pittman, 2005), and was 
recently shown to interact with tubulin and microtubule-associated protein 2 (MAP2), 
two other constituents of the cytoskeleton (Mazzuchelli et al., 2009). It has been 
proposed that atx3 may protect misfolded proteins before they reach the MTOC, or 
stabilize proteins involved in the transport (Burnett & Pittman, 2005). 
 
1.2.3.3 – Involvement in transcription regulation 
 
A different aspect of atx3 function concerns its role as a possible transcription 
regulator. In fact, atx3 has been shown to be able to regulate expression of a great 
number genes (Evert et al., 2003; Rodrigues et al., 2007). A microarray analysis using 
two different Caenorhabditis elegans strains KO for the worm ortholog of atx3 identified 
290 genes (1.4% of the worm total genome) that are differentially expressed comparing 
to wild-type animals. 143 of these had unknown function, but the other 147 genes were 
grouped according to their proposed biological roles: cell structure and mobility 
components (50%), signal transduction (20%), the UPP (8%), and other cell processes 
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(22%), which include genes encoding enzymes, transporters, receptors and channels 
involved in diverse pathways. Of the 290 differentially expressed genes, 253 were up-
regulated and 37 were down-regulated (Ferro et al., 2007; Rodrigues et al., 2007). 
Even though there was a clear transcriptional deregulation in the KO strains, in 
resemblance with the KO mice mentioned above, the animals were viable and had no 
overt phenotype, probably due to functional redundancy and adaptative modifications. 
Atx3 function as a transcription regulator is also supported by some studies 
concerning its molecular interactions (Burnett et al., 2003; Li et al., 2002). Atx3 
interacts with three transcription activators - cAMP response element-binding protein 
(CREB)-binding protein (CBP), p300 and p300/CBP-associated factor (PCAF), the 
major histone acetyltransferases - through its C-terminal region (Li et al., 2002), with 
two transcription repressors - histone deacetylase 3 (HDAC3) and nuclear receptor co-
repressor (NCor) - in an interaction involving its UIMs (Evert et al., 2006a), and with 
histones, mainly through the N-terminal (Li et al., 2002). The same studies report that 
atx3 represses the transcription mechanisms mediated by these proteins through 
different processes. Histone acetylation is a means of controlling gene transcription: 
increased acetylation renders chromatin conformation sparser, enhancing its 
transcription, while decreased acetylation turns it denser, obstructing the access of 
important regulatory factors. CBP, p300 and PCAF are transcriptional co-activators that 
form complexes with other co-activators and proteins with acetyltransferase activity and 
acetylate histones; atx3 seems to repress transcription mediated by these co-activators 
through binding of these proteins through its C-terminal. Furthermore, binding of 
histones trough the N-terminal seems to repress acetylation by blocking the access to 
acetylation sites present in the histone proteins (Li et al., 2002; Nicastro et al., 2005). 
Atx3 interaction with HDAC3 and NCor was also reported to somehow lead to a 
decrease in histone acetylation and consequent transcription repression (Evert et al., 
2006a).  
Introduction 
23 
 
Interestingly, there are some studies that expose an association between 
transcription regulation and the UPP, though there is no clear evidence for such 
connection in the case of atx3 (Burnett et al., 2003). It has been hypothesized, 
however, that atx3 deubiquitinating activity may help stabilize transcription regulators 
(Evert et al., 2006a; Rodrigues et al., 2007). 
In a tentative approach to summarize what has been exposed about the 
possible biological roles of atx3, it can be said that current evidences connect its 
function to a) the UPP, with some studies pointing out an important participation in the 
ERAD and aggresome formation, and to b) transcriptional regulation. 
 
1.2.4 – Intracellular localization and transport 
 
In addition to the ubiquitous distribution of atx3 among tissues, the protein 
seems to be widely, though heterogeneously, distributed within the cells themselves, 
being found in the cytoplasm (mitochondria included) and the nucleus, with varying 
degrees of predominance depending on the cells in question (Macedo-Ribeiro et al., 
2009; Paulson, et al., 1997b; Pozzi, et al. 2008; Tait et al., 1998; Trottier et al., 1998; 
Wang et al., 1997). In human brain cells observations, atx3 localized mainly in the 
perikarya, though, depending on the analyzed cells, it was also detected on proximal 
processes, axons and nuclei. This heterogeneity suggests that regulation of atx3 
expression level and localization may be functionally important (Trottier et al., 1998).  
Recent studies demonstrated that atx3 is actively transported across the 
nuclear envelop, being shuttled from the cytoplasm to the nucleus and vice-versa 
(Antony et al., 2009; Macedo-Ribeiro et al., 2009). Regarding nuclear importation, a 
functional nuclear localization signal (NLS) promoting atx3 transport to the cell nucleus 
has been detected immediately upstream the polyQ sequence (R282-R285) (Tait et al., 
1998; Boeddrich et al., 2006; Macedo-Ribeiro et al., 2009). Nuclear exportation 
appears to integrate both chromosome region maintenance 1 (CRM1)-dependent and 
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independent mechanisms (Macedo-Ribeiro et al., 2009) and, as of yet, two apparently 
functional nuclear export signals (NES) have been reported (I77-Y99 and E141-E158), 
though without consensus (Antony et al., 2009; Macedo-Ribeiro et al., 2009). 
 
1.3 – Expanded ataxin-3 and Machado-Joseph disease pathogenesis  
 
 To this date, the way through which polyQ expanded atx3 leads to MJD 
pathogenesis has not been clarified, though, as for every other polyQ disease, the 
unstable expansion is admittedly of causative importance. There are several 
observations supporting this idea: a) the polyQ disease proteins’ sequence is dissimilar 
outside the polyQ tract; b) diseases’ severity increases with glutamine repeat number; 
c) age of onset decreases with the increase of repeat number; d) several transgenic 
models expressing polyQ sequences outside the natural gene context present 
neurodegenerative phenotypes (Ikeda et al., 1996; Mangiarini et al., 1996; Ordway et 
al., 1999; Paulson et al., 1997b). As stated above, however, though the polyQ 
sequence expansion appears to be the triggering factor leading the development of 
MJD, atx3 regions outside the polyQ domain and the protein properties they determine 
are sure to define the development of the disease (Gatchel & Zoghbi, 2005; Shao and 
Diamond, 2007). 
 The different hypothesis and evidences regarding MJD pathogenesis are 
discussed below. 
 
 1.3.1 – Protein aggregates and nuclear inclusions 
 
Studies suggest that expanded atx3 and every other polyQ expanded protein 
tend to form toxic aggregates, as a result of polyQ expansion-induced misfolding and 
consequent transition to aggregation-prone conformations (Bevivino & Loll, 2001; Chen 
et al., 2002b; Chow et al., 2004c; Jana & Nukina, 2004; Tanaka, et al., 2001). 
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Investigation has focused on a search to comprehend the mechanisms underlying atx3 
aggregation, but, to this date, the understanding of such subject is still limited, with 
many mechanisms being proposed for the fibrillogenesis process (Chen et al., 2002b; 
Ellisdon et al., 2007; Gales et al., 2005). Curiously tough, even non-expanded atx-3 
and the JD itself display tendency to aggregate (Masino et al., 2004; Gales et al., 
2005). Aggregation may result from a monomeric thermodynamic nucleus formed by a 
single misfolded protein to which monomers are added, consequently leading to 
elongation and fibril formation; in the case of the expanded protein there is a second 
aggregation step that leads to the formation of more stable aggregates (Ellisdon et al., 
2007) (Figure 3). In healthy people, the slow aggregation kinetics of the non-expanded 
atx3 and the high instability of the aggregates formed shall ensure an effective break 
down by the cell’s intrinsic quality-control mechanisms. Conversely, in MJD patients, 
the enhanced kinetics of the expanded atx3 aggregation as well as the great stability of 
the aggregates formed shall lead to their aberrant accumulation inside the cells. This 
accumulation may increase with aging, as a result of the progressive failure of quality-
control mechanisms (Ellisdon et al., 2006; Ellisdon et al., 2007; Gales et al., 2005; 
Masino et al., 2004). 
As mentioned before, one common feature to all polyQ expansion diseases is 
the formation of large macromolecular aggregates containing the pathogenic protein. 
Even though wild-type atx3 displays a wide distribution within the cell, in MJD patients’ 
brains, atx3 amasses in the form of nuclear inclusions (NIs) present only in neurons 
(Paulson et al., 1997b). Apart from the polyQ expanded atx3, NIs contain several other 
proteins, namely members of the cell quality-control systems, like proteasome 
constituents and molecular chaperones (Chai et al., 1999a; Chai et al., 1999b; Chow et 
al., 2004a; Muchowski et al., 2000; Schmidt et al., 2002; Zander et al., 2001). 
Intracellular inclusions have been often linked to the pathogenesis of polyQ diseases 
as a major means of polyQ toxicity because of their ability to sequester different 
molecules, provoking citotoxicity through several possible mechanisms: a) hindrance of 
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Figure 3 – Schematic representation of a possible atx3 fibrillogenesis 
pathway. When atx3 is in its native state, the JD and the UIMs are 
represented as a triangle and the polyQ tract as a predominantly random coil 
tail. Fibril formation is initiated by a monomeric thermodynamic nucleus 
formed as a result of structural changes occurring on the non-polyQ regions 
of the protein (represented by the square-shaped JD). This first-step of atx3 
elongation occurs down an energy gradient by the addition of atx3 
monomers to the growing fibril. PolyQ expanded atx3 undertakes a second 
aggregation stage, marked by the participation of the polyQ tract in the 
aggregation process and a large increase in size and stability of the amyloid-
like fibrils. (Adapted from Ellisdon et al., 2007) 
transcription, through sequestration of molecules involved in transcription regulation  
(Chai et al., 2002; McCampbell et al., 2000); b) a general disturbance of the quality-
control systems of the cells, due to sequestration of proteasome constituents and 
molecular chaperons (Chai et al., 1999a; Chai et al., 1999b; Ferringo & Silver, 2000; 
Muchowski et al., 2000; Paulson, et al., 1997b; Schmidt et al., 2002; Warrick et al., 
1999); c) hindering of axonal transport, resulting from motor protein titration and 
physical blocking (Gunawardena et al., 2003); d) other disturbs caused by recruitment 
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of Ub-binding proteins (since inclusions are heavily ubiquitinated) or other polyQ-
containing proteins (Donaldson et al., 2003; Perez et al., 1998). 
Nonetheless, the importance of these large macromolecular aggregates to 
polyQ disease pathogenesis is recently being disputed (Shao & Diamond, 2007). Many 
authors suggest that they are in fact the result of protective cellular mechanisms moved 
as a measure of the cell to cope with the toxicity of the expanded proteins, provoked by 
other agents. Studies concerning MJD demonstrate that there is no perfect overlap 
between the brain regions that degenerate and the regions presenting NIs (Evert et al., 
2006b; Paulson et al., 1997b; Ross & Poirier, 2004; Trottier et al., 1998; Yamada et al., 
2001). Furthermore, research into HD revealed that inclusion formation even 
associates with the survival of the corresponding cells (Slow et al., 2005; Arrasate et 
al., 2004). 
Nowadays, in the matter of atx3 aggregation (and polyQ protein aggregation in 
general), the small aggregates or oligomers are the ones envisioned as the actual toxic 
species causing cytotoxicity. Importantly, to this date several atx3 oligomers and 
multimers have already been isolated (Gales et al., 2005). Atx3 aggregates are β-rich 
fibrillar structures of amyloid nature, reminiscent of the amyloid aggregates observed in 
Alzheimer’s and prion diseases (Bevivino and Loll, 2001; Chen et al., 2002a). It is 
suggested that the soluble amyloid oligomers have an inherent toxicity caused by 
mechanisms common to all of them (Kayed et al., 2003), for example being able to 
destabilize the lipid bilayer, increasing its conductivity (Demuro et al., 2005; Kayed et 
al., 2004). Sequestering of quality-control system components and transcription factors 
have also been pointed out as possible causes of toxicity, as they lead to proteotoxic 
stress and transcriptional deregulation (Schaffar et al., 2004; Shao & Diamond, 2007) 
(Figure 4). The cell-mediated formation of NIs, though directed as an adaptive 
response, may instead take part in some kind of snowball effect, in which even more 
proteins are sequestered and more cellular systems become dysfunctional. 
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1.3.2 – Proteolytic cleavage and toxic fragment hypothesis 
 
Several studies suggest that the proteolytic cleavage of polyQ disease proteins 
can contribute to their pathogenesis, the resulting fragments being of crucial 
importance for their aggregation and cytotoxicity; this idea is referred to as the toxic 
fragment hypothesis (Tarlac and Storey, 2003; Wellington et al., 1998) (Figure 4). 
In effect, atx3 cleavage appears to increases its aggregation, with caspases 
and calcium-dependent calpain proteases being pointed as the enzymes possibly 
responsible for that process (Berke et al., 2004; Haacke et al., 2006; Haacke et al., 
2007). Removal of the N-terminus of expanded atx3 was shown to be important for 
protein aggregation (Haacke et al., 2006). Cleavage appears to result in polyQ-
containing C-terminal fragments that are toxic by themselves, and a peptide of this kind 
has been identified as more abundant in affected brain regions of MJD patients 
(Colomer Gould et al., 2007; Goti et al., 2004; Yoshizawa et al., 2000).  
Contrastingly, recent studies demonstrated that, although all atx3 forms suffer 
some common proteolytic processes, expanded atx3 is cleaved to a lesser extent when 
compared with the normal atx3 (Pozzi et al., 2008). 
 
1.3.3 – Ataxin-3 polyglutamine expansion-induced property changes 
 
It is also possible that the polyQ expansion of atx3 interferes with the protein, 
producing changes in its function, interactions or localization that lead to cellular toxicity 
and play important roles in the development of MJD.  
A first hypothesis could be that atx3 expansion leads to a loss of protein 
function and that this would be sufficiently significant to cause the disease. However, 
the mouse and C. elegans KOs seem to indicate that atx3 function is not crucial for the 
cells, as the animals present no overt phenotype (Rodrigues et al., 2007; Schmitt et al., 
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Figure 4 – Pathogenesis of polyQ expansion diseases. Many polyQ 
diseases appear to start from a proteolytic cleavage event that generates 
toxic fragments. The expanded polyQ sequence then allows transition into a 
misfolded conformation and the peptide may exert toxicity as a monomer or 
it may self-assemble and constitute toxic oligomers. Continued aggregation 
leads to deposition into larger macromolecular inclusions. Misfolded protein 
and aggregates may disrupt several cellular systems. (Adapted from Shao et 
al., 2007) 
2007). Other hypothesis is that the expanded polyQ changes the protein’s function in a 
way that it alters its cellular activity, actively causing cell death. 
Atx3 has been linked with the UPP and, in line with what has been said above, 
disturbance of this pathway is a possible cause of toxicity, as it might interfere with the 
normal turnover and degradation of proteins. Studies have demonstrated that there are 
not much significant differences in the deubiquitinating activity between normal and 
expanded atx3 (Berke et al., 2004; Burnett et al., 2003). Expanded atx3 retains its 
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ability to bind polybiquitinated substrates in a UIM-dependent manner, with no global 
differences comparing to the normal protein (Berke et a., 2004). Nonetheless, the 
possibility that the two forms may bind differentially to particular substrates is not to be 
ruled out.  
Atx3 participation in the UPP adds an interesting aspect to MJD: atx3 shall be 
presented to misfolded and aggregated proteins as part of its normal function, but 
possible stable interactions between them and the expanded protein may potentiate 
protein aggregation and constitute a cause for dysturbance of proteasomal function 
(Burnett et al., 2003; Burnett & Pittman, 2005). The presence of Ub and proteasome 
constituents in the protein NIs can partially be explained by the fact that atx3 
physiologically interacts with them (Doss-Pepe et al., 2003). 
Another aspect where an expanded polyQ tract may influence atx3 properties, 
possibly influencing its physiological role, is the interactions atx3 establishes. HHR23A 
and HHR23B binding is not affected by the polyQ expansion, but HHR23A co-localizes 
with expanded atx3-containing aggregates in cell lines (Wang et al., 2000). PolyQ tract 
expansion increases the extent of the interaction with p97/VCP, which also co-localizes 
with the NIs in MJD patients (Boeddrich et al., 2006). These interaction changes are 
likely to cause an altered distribution pattern of these interactors and influence their 
activity and other molecular interactions (Boeddrich et al., 2006; Higashiyama et al., 
2002; Hirabayashi et al., 2001; Wang et al., 2000). Impairement of the ERAD caused 
by expansion of atx3 may induce endoplasmic reticulum proteotoxic stress that may 
contribute to the degenerative mechanisms (Wang et al., 2006; Zhong & Pittman, 
2006). 
PolyQ expansion may also influence atx3 proposed function as a transcription 
regulator. Expansion may alter atx3 binding properties and compromise its ability to 
establish transcription repressor complexes, leading to the increased expression of 
certain genes, some of which may contribute to the disease. The expanded form of 
atx3 appears to bind chromatin in different places and to aberrantly increase 
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transcription in cells (Evert et al., 2003; Evert et al., 2006a). Histone acetylation is 
increased in cells expressing expanded atx3 and human MJD pons, although both 
normal and expanded forms associate with HDAC3 and NCoR (Evert et al., 2006a). 
Expanded atx3 is also reported to bind transcriptional co-activators (CBP, p300 and 
PCAF) to a greater extent than the non-expanded form, though its inhibitory effect on 
transcription was similar (Li et al., 2002). Importantly, MJD patients’ brains have been 
reported to show transcriptional deregulation of several genes (Evert et al., 2001; Evert 
et al., 2006b; Wen et al., 2003). A direct example of the negative effect of transcription 
comes from studies relating apoptosis with the cell loss observed in MJD, as expanded 
atx3 was reported to upregulate the Bax protein (a pro-apoptotic protein), while 
downregulating Bcl-xL levels (an anti-apoptotic protein), in cultured neurons (Chou et 
al., 2006). 
 
1.3.4 – Ataxin-3: a protector against polyglutamine toxicity?  
 
In resemblance with other polyQ diseases, it has been determined that, apart 
from expanded atx3, protein aggregates seen in MJD also present normal atx3 
(Fujigasaki et al., 2000); this is possible because MJD and other polyQ diseases are 
autosomal dominant diseases, and so both normal and expanded forms can be present 
in the same cell. This situation can reflect the importance of regions outside the polyQ 
tract in the aggregation mechanism or result from conformational changes that the 
misfolded expanded atx3 induces in the non-expanded protein, leading to its 
recruitment to the forming aggregates (Chow et al., 2004a).  
Another possibility, however, would be that atx3 is recruited to this aggregates 
because of the UIMs (inclusions are highly ubiquitinated) and/or because of its 
involvement in the UPP, being required by cellular mechanisms mobilized to deal with 
the aggregates (Burnett et al., 2003; Burnett & Pittman, 2005; Donaldson et al., 2003; 
Fujigasaki et al., 2001; Warrick et al., 2005). Consistently with this, a striking feature of 
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atx3 that should be considered when studying its biological role and MJD pathogenesis 
is that this protein co-localizes with aggregates formed in other polyQ expansion 
diseases (Uchihara et al., 2001) and in other neurodegenerative states (Burnett et al., 
2003; Fujigasaki et al., 2000; Pountney et al., 2003; Seilhean et al., 2004; Takahashi et 
al., 2001).  
Importantly, an interesting study by Warrick and co-workers (Warrick et al., 
2005) strongly suggested that atx3 may have a protective role against polyQ toxicity. 
They reported that flies resulting from crosses between individuals expressing 
expanded atx3 or other expanded polyQ-disease proteins and individuals expressing 
non-expanded atx3 did not present the symptoms their diseased relatives had. This 
suggested that atx3 was able to mitigate toxicity in several Drosophila polyQ diseases 
models, including a MJD model. The protective activity may be linked to atx3 
involvement in quality-control mechanisms such as the UPP, as it requires normal 
proteasome functionality and Ub-associated activities, including Ub protease activity 
and UIM functionality. These results may further explain why MJD patients with two 
pathogenic alleles have more severe phenotypes than heterozygotic patients (Lang et 
al., 1994); the phenotype of homozygotic patients may result not only from the two 
pathogenic alleles but also from a loss of that protective function (Warrick et al., 2005).  
 
1.3.5 – The role of cellular and protein contexts 
 
Although both normal and expanded forms of atx3 display an ubiquitous and 
similar expression throughout the body (particularly in the brain), like it has been said 
before, cell loss occurs only in selective parts of the nervous system (Paulson et al., 
1997a; Trottier et al., 1998; Wang et al., 1997). The same thing has been reported for 
other polyQ expansion diseases, and such observations point out to a very important 
feature of these diseases’ group: the role of cellular context. Pathogenic protein 
expression by itself is not sufficient to cause degeneration and so the whole 
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environment of the cell, and the way it interacts with the expanded protein, may be 
relevant for the pathogenic mechanisms. These facts relate to yet another, recurring, 
observation: although polyQ sequences are toxic by themselves, different diseases, 
with different associated proteins, have different disease phenotypes, explained by the 
importance of the other regions of the host protein, i e, the host protein context 
(Gatchel & Zoghbi, 2009; La Spada & Taylor, 2003). Taking this all together, the way a 
particular protein acts in the particular environment of each cell determines the 
specificities of the development of a particular polyQ disease and its distinctiveness 
from other diseases of this type. As such, properties like the protein’s biological 
functions, interactions and localization, and the influence the expanded polyQ stretch 
has upon them, may conjugate with particular cellular contexts and lead to different 
outcomes, being crucial to pathogenesis. 
In the case of MJD, many reports related with this subject focus the role of 
subcellular localization of atx3 in the development of the disease. Although nuclear 
localization of atx3 is not sufficient to cause the disease (Trottier et al., 1998), early 
studies reported that a non-expanded atx3 fragment targeted to the nucleus leads to 
aggregate formation, suggesting that the nuclear environment may be important in this 
event (Perez et al., 1998; Perez et al., 1999). Recent studies using transgenic mice 
demonstrated that targeting expanded atx3 to a nuclear localization aggravates the 
disease phenotype, while nuclear export reduces it (Bichelmeier et al., 2007). This 
implies that nuclear localization of atx3 is necessary for the manifestation of MJD 
symptoms in vivo. 
 
1.4 – Post-translational modifications of ataxin-3 
 
An emerging way by which the host protein context may be important in the 
development of polyQ expansion diseases relates to its potential susceptibility to suffer 
post-translational modifications (PTMs) (La Spada & Taylor, 2003; Pennuto et al., 
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2009). PTMs consist of several mechanisms of enzymatic processing of proteins that 
occur during or after protein synthesis. They comprise a huge variety of processes, 
including proteolytic cleavage, addition or removal of amino acids, attachment of 
oligosaccharides or prosthetic groups, and addition of chemical groups or other 
proteins to certain amino acid residues. PTMs contribute to the formation of the mature 
protein and determine some of its properties, including subcellular localization, activity, 
interactions and stability. Some of them are reversible and play an important role in the 
cellular dynamics of the protein they modify, reversibly modulating some of its 
properties.  
Logically, since PTMs constitute a group of key regulatory mechanisms 
modulating the activity of so many proteins, one can expect atx3 itself to be the target 
of some PTMs that alter its properties. The regulation of atx3 activity by PTMs is a very 
important aspect to consider when studying its possible functions, attending to the fact 
that DUB activity is highly regulated, since their protease activity must be correctly 
directed in order to ensure correct cleavage of the proper substrates (Reyes-Turcu, et 
al., 2009). Along with transcription, molecular interactions, degradation and proteolytic 
cleavage, PTMs are admitted as one possible mechanism regulating DUB activity, and 
to this date, many enzymes belonging to this group have been shown to be modulated 
by this kind of modifications (Nijman et al., 2005; Reyes-Turcu et al., 2009). PTMs can 
be predicted as mechanisms possibly responsible for enhancing atx3 activity in the 
proper cellular context; their absence may explain the low activity of atx3 reported in 
the experiments (Macedo-Ribeiro S., unpublished data). Furthermore, interaction of the 
DUBs with other proteins (scaffolds or adapters) has also been pointed out as an 
important mechanisms for DUB activation and the correct placement of substrate 
molecules relatively to the catalytic site, thus making up for the possible low affinity with 
the substrates (Reyes-Turcu, et al., 2009). PTMs may be important in regulating these 
molecular interactions, thus ultimately interfering with atx3 activity. PTMs may also 
regulate atx-3 subcellular localization, therefore explaining the diversity in intracellular 
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distribution observed both in cell lines and human brain cells (Macedo-Ribeiro et al., 
2009; Paulson, et al., 1997b; Pozzi, et al. 2008; Tait et al., 1998; Trottier et al., 1998; 
Wang et al., 1997). This may constitute yet another indirect mechanism by which PTMs 
regulate atx3 function, considering that subcellular localization is another factor 
influencing DUBs activity (Reyes-Turcu et al., 2009). 
Given the central role of PTMs in the cellular dynamics, it can be expected that 
these modifications modulate the mechanisms by which expanded polyQ proteins lead 
to the related diseases, in part participating in the processes by which different proteins 
determine the specificities of each polyQ disease (Pennuto et al., 2009). In fact, thus 
far there have been several PTMs associated with polyQ disease proteins, including 
proteolytic cleavage (referred above), phosporylation, acetylation, ubiquitination, 
sumoylation, palmitoylation and transglutamination (Figure 5). Concordantly, PTMs 
may provide clues to how expanded atx3 leads to MJD, through their influence in atx3 
properties (Gales et al., 2005; La Spada & Taylor, 2003). Possible changes may again 
be related to atx3 enzymatic activity, interactions and localization, but also to its 
stability and propensity to form aggregates, among other things. As explained above, 
different levels of some PTMs between different cells may partly explain the regional-
specificity of MJD. Finally, it can also be expected that some modifications important 
for the development of the disease may constitute possible targets for rational 
therapeutic interventions (La Spada & Taylor, 2003). 
The following subsection will briefly analyze what is currently known about atx3 
ubiquitination; since this PTM has been reported to be involved in atx3 degradation and 
activity, its study contributes to a better understanding of atx3 cellular functions and the 
possible effects PTMs have on them. The last two subsections will discuss what is 
currently known about the two modifications focused in the current work - 
phosphorylation and sumoylation - as regulators of several polyQ disease proteins. We 
will analyze what has been proposed as their physiological role in the different protein 
contexts and what is their potential influence in the polyQ expansion diseases 
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Figure 5 – PTMs of polyQ-containing proteins and their influence in 
pathogenesis. PolyQ proteins may be targeted by several PTMs, including 
phosphorylation, acetylation, ubiquitination, sumoylation, palmitoylation and 
transglutamination. The way these modifications affect protein properties 
and cellular dynamics can produce either neurotoxic or neuroprotective 
effects. (Pennuto et al., 2009) 
pathogenesis mechanisms. Data regarding phosporylation and sumoylation of atx3 will 
be handled with particular detail, but as these studies are still very limited, reports 
about those other polyQ diseases’ proteins shall be envisioned as sources of possible 
clues to the relevance of PTMs for atx3 function and MJD development.  
 
1.4.1 – Ubiquitination and clues to regulation of ataxin-3 turnover and 
activity  
 
Up until now, many authors have focused on the study of atx3 ubiquitination 
and its relation with the protein stability and degradation. As described above, 
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ubiquitination is a common PTM consisting in the covalent attachment of Ub molecules 
or polyUb chains to one or several lysine residues of another protein.  A primary role of 
ubiquitination is the targeting of defective proteins or those with short half-lives for 
degradation in the proteasome (Schnell & Hicke, 2003; Weissman, 2001). Atx3 has 
been shown to be itself polyubiquitinated and to be (at least partially) degraded by the 
proteasome (Berke et al., 2005; Jana et al., 2005; Matsumoto et al., 2004; Todi et al., 
2007; Tsai et al., 2003). One study demonstrated that the expanded protein is more 
stable than its non-expanded counterpart and that it is degraded by the proteasome 
less efficiently; this must contribute to the accumulation of the pathogenic protein and 
persistence of its toxic effects (Matsumoto et al., 2004). Interestingly, atx3 catalytic 
activity appears to somehow regulate its turnover, since catalytically inactive atx3 was 
reported to have higher steady state levels in cells, partially resulting from a reduction 
on degradation (Todi et al., 2007). Strikingly, however, in both cases and in several 
other studies (Berke et al., 2005; Miller et al., 2004), increased ubiqutination did not 
correlate with increased degradation. This may indicate that proteasomal degradation 
independently of ubiquitination may be important in these situations (Todi et al., 2007) 
or, in the case of the expanded protein, the differences observed may be due to a 
inefficient proteosomal recognition and degradation due to the expanded polyQ tract 
(Matsumoto et al., 2004).  
 As described, ubiquitination is not limited to targeting proteins for proteasomal 
degradadion. UIM-containing proteins are often subject of ubiquitination processes 
different from the classical lysine 48-linked polyubiquitination, suggesting that UIMs 
may mediate them (Miller et al., 2004). Berke and co-workers (Berke et al., 2005) 
demonstrated that atx3 is ubiquitinated under normal conditions, and concluded that 
the observed ubiquitination corresponded to mono or oligoubiquitination (likely short 
chains or several single Ub molecules attached to different lysine residues); this 
process was facilitated by functional UIMs. Importantly, there is some evidence that 
UIM-dependent ubiquitination inhibits the interaction between UIM-containing proteins 
Introduction 
38 
 
and other ubiquitinated proteins (Miller et al., 2004). The aforementioned study (Berke 
et al., 2005) also reported the presence of some lower molecular weight ubiquitinated 
species that were not abolished by UIM blockade and were suggested to correspond to 
monoubiquitination. Recent results by our group demonstrated that atx3 JD is 
monoubiquitinated in vitro, and such modification may account for those UIM-
independent monoubiquitinated forms (Moreira, 2007). Endogenous atx3 was recently 
described to be monoubiquitinated in neural cells (Todi et al., 2009). 
Though the possible function of these alternative forms of ubiquitination is not 
well understood, this same recent report demonstrated that atx3 ubiquitination 
increases its DUB activity, independently of potential cofactors or interactors (Todi et 
al., 2009). Interestingly, though the UIMs are important in determining cleaving 
preferences, this activity enhancement appears to be independent from the 
functionality of these motifs and from the length of the polyQ tract, and 
monoubiquitination was demonstrated to be enough to produce the effect. Further 
observing that several proteotoxic stressors enhanced atx3 ubiquitination, the authors 
suggested that the upregulation of atx3 activity by ubiquitination may serve as a 
negative feedback mechanism in the response to those kinds of cellular threats. 
Importantly, studies demonstrate that atx-3 is not targeted by its own DUB activity in 
trans, opposing the possibility of atx3 regulating its own activity through regulation of its 
ubiquitination status (Todi et al., 2007). 
 One other mechanism possibly related to atx3 ubiquitination is connected with 
its interaction with several E3 Ub ligases, the enzymes responsible for forming the 
isopeptide bonds between Ub molecules and the lysine residues of target proteins or 
other Ub molecules, forming polyUb chains. Atx3 (or polyQ expanded fragments of the 
protein) have been shown to interact with several Ub ligases - C-terminus of 70 KDa 
heat shock protein (Hsp70)-interacting protein (CHIP), parkin, E4B and Hrd1 – and 
these enzymes (the exception being Hrd1) were shown to promote atx3 ubiquitination 
and degradation (Jana et al., 2005; Matsumoto et al., 2004; Miller et al., 2005; Tsai et 
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al., 2003; Wang et al., 2006). These activities were further related with decrease of 
expanded atx3 aggregation and polyQ toxicity but, attending to what has been seen for 
one complex formed by a DUB and a E3 enzyme (Ub-specific protease 4 - Usp4 - and 
Rho52, respectively), one can speculate that atx3 and the Ub E3 ligases with which it 
interacts may transregulate each other as part of their normal function (Wada & 
Kamitani, 2006). The E3 enzymes may be responsible for regulating atx3 activity or 
targeting it to degradadion through promotion of its ubiquitination, while atx3 may edit 
polyUb chains added to other E3 ligase substrates and regulate the ubiquitination state 
of the E3 ligases themselves (Reyes-Turcu et al., 2009; Todi et al., 2009; Wada & 
Kamitani, 2006). 
 
 1.4.2 – Phosphorylation of polyglutamine disease proteins 
 
 Phosphorylation is a common PTM that regulates protein function, activity, 
molecular interactions and subcellular localization, among other properties, in an acute 
and reversible way. It consists in the addition of a phosphate group to the hydroxyl 
group of a serine, threonine or tyrosine residue of a protein; protein kinases catalyze 
the addition of such group, while protein phosphatases catalyze the reverse 
phenomenon, i e, dephosphorylation. The alterations phosphorylation causes are due 
to conformational changes induced by the presence of the negative-charged phosphate 
group.  
 Protein phosphorylation seems to play an important role in many different 
neurodegenerative diseases. Many proteins related to the pathogenesis of polyQ 
expansion diseases have been found to be phosphorylated by certain kinases, and 
such phenomenon seems to be of great importance for the mechanisms involved in the 
diseases (Table II). 
 Phosphorylation of serine 776 of ataxin-1, the protein responsible for SCA1, 
seems to have a critical role on the pathogenesis of this disease, enhancing 
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Table II: Phosphorylation of proteins involved in polyQ expansion 
diseases (based on the studies referenced in the text)  
Disease 
name 
Protein 
product 
Phosphorylation 
sites Kinase Described Effects 
HD Huntingtin 
S412 Akt, SGK Rescues axonal transport and toxicity  
S434 Cdk5 Reduces cleavage by caspases and toxicity 
S531 --- Reduces cleavage by caspases and toxicity 
S1181 
Cdk5 Reduces toxicity 
S1201 
T3 --- Increases aggregation, but reduces toxicity 
DRLPA Atrophin-1 S734 JNK --- 
SBMA Androgen receptor 
S215 
Akt 
Reduces ligand binding, nuclear 
translocation, transcriptional 
activation, toxicity and 
aggregation; increases 
degradation 
S792 
S416 --- Increases toxicity of the expanded form 
S516 MAPK Increases cleavage by caspases and toxicity of the expanded form 
S651 --- 
Promotes transcriptional 
activation and nuclear 
translocation 
Y267 
Ack1 Promotes cancer cell proliferation 
Y363 
Y534 SRC 
Promotes transcriptional 
activation, nuclear translocation 
and proliferation of prostate 
cancer cells 
SCA1 ataxin-1 S776 Akt Decreases degradation 
MJD/ 
SCA3 ataxin-3 
S236 
CK2 Increases nuclear transport, NI formation and gene repression S340 
S352 
S256 GSK3β Reduces aggregation 
 
Abbreviations: HD, Huntington’s disease; DRPLA, dentatorubral-pallidoluysian atrophy; SBMA, 
spinal and bulbar muscular atrophy; SCA, spinocerebellar ataxina; MJD, Machado-Joseph 
disease; SGK, serum/glucocorticoid regulated kinase; Cdk5, cyclin-dependent kinase 5; JNK, c-
Jun NH2-terminal kinase; MAPK, mitogen-activated protein kinase; SRC, steroid hormone 
receptor coactivator; CK2, casein kinase 2; GSK3β, glycogen synthase kinase 3. --- indicates 
absence of data. 
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aggregation of an expanded form of the protein (Emamian et al., 2003). Akt 
phosphorylation of this residue leads to the binding of 14-3-3 protein, which stabilizes 
ataxin-1 and slows down its degradation (Chen et al., 2003). It was further 
demonstrated that an expanded ataxin-1 phospho-dead mutant for that serine residue 
expressed in Purkinje cell nuclei of mice is less capable of inducing the disease; the 
mutation reduces its toxic effects and its accumulation into NIs (Emamian et al., 2003). 
Huntingtin, the protein whose expanded form is responsible for HD, is already 
known to be phosphorylated in several residues: serines 421, 434, 536, 1181, 1201, 
2076, 2653 and 2657 and threonine 3 (Aiken et al., 2009; Anne et al., 2007; Luo et al., 
2005; Rangone et al., 2004; Schilling et al., 2007; Warby et al., 2005).  Serine 412 is 
known to be phosphorylated by Akt and serum/glucocorticoid regulated kinase (SGK) 
(Rangone et al., 2004; Warby et al., 2005), while serines 434, 1181 and 1201 are 
phosphorylated by cyclin-dependent kinase 5 (Cdk5) (Anne et al., 2007; Luo et al., 
2005). So far, studies concerning the role of huntingtin phosphosrylation point out to a 
protective function for this PTM. Initial studies demonstrated that Akt phosphorylation of 
huntingtin has a protective effect, reducing inclusion formation and cell death caused 
by expanded huntingtin (Humbert et al., 2002). Later, it was also demonstrated that 
phosphorylation of serine 421 of an expanded huntingtin fragment had a 
neuroprotective effect in vivo; calcineurin dephosphorylates that residue in vitro and in 
cells and inhibition of calcineurin prevented cell death of striatal neurons caused by 
expanded huntingtin (Ermak et al., 2009; Pardo et al., 2006). This protective effect may 
be related to the recently described ability of phosphorylated serine 421 to rescue the 
impairment of axonal transport caused by expanded huntingtin (Zala et al., 2008). SGK 
phosphorylation also has a protective effect against the toxicity induced by expanded 
huntingtin, in striatal neurons (Rangone et al., 2004). Phosphorylation of serine 434 
reduces huntingtin cleavage by caspases, thus attenuating protein aggregation and 
toxicity (Luo et al., 2005), and the same was suggested for serine 536 (Schilling et al., 
2007). Phosphorylation of threonine 3 and serines 1181 and 1201 was shown to 
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protect against expanded huntingtin (Aiken et al., 2009; Anne et al., 2007) and, 
additionally, lack of phosphorylation of these two serine residues confers toxicity even 
to the wild-type huntingtin (Anne et al., 2007). Deficiences regarding phosphorylation 
were also linked with disease phenotype in observations of HD animal models and 
patients brain tissue: Cdk5 activity is reduced in the brains of HD animal models (Luo 
et al., 2005), while, in human patients, Akt is altered (a shorter form appears) and the 
levels of calcineurin inhibitors decreased (Humbert et al., 2002). Finally, it was 
proposed that the observed differential levels of serine 421 phosphorylation between 
different parts of the brain (in both human and mouse brain, under normal conditions), 
along with the fact that cell culture models show reduced levels of endogenous 
phosphorylation of the disease protein, may explain the selective neuronal loss 
observed in HD (Warby et al., 2005). 
Atrophin-1, the protein responsible for DRPLA, appears to be phosphorylated 
by c-Jun NH2
 Many phosphorylation sites have already been mapped in the androgen 
receptor (AR), the protein involved in SBMA: serines 16, 83, 96, 215, 258, 310, 426, 
516, 651 and 792, and tyrosines 223, 267, 307, 346, 357, 362/363, 393, 534, 551, 915 
(Gioeli et al., 2002; Guo et al., 2006; Palazzolo et al., 2007; Pennuto et al., 2009). In 
some cases, phosphorylation has been related to the functionality of the AR: 
phosporylation of serine 651 appears to modulate AR transcriptional activity by 
regulation of its nuclear exportation (Gioeli et al., 2006), while phosphorylation of 
tyrosine 534 (apparently phosphorylated by steroid hormone receptor coactivator  - 
SRC) was shown to regulate not only AR transcriptional activity and nuclear 
translocation, but also proliferation of prostate cancer cells (prostate cancer is another 
disease related to the AR) (Guo et al., 2006). Tyrosines 267 and 363 are posphorylated 
-terminal kinase (JNK) at serine 734, but the affinity of that enzyme is 
reduced when the polyQ expansion is present. The resulting slower phosphorylation 
may delay processes responsible for keeping neurons alive (Okamura-Oho et al., 
2003). 
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by Ack1 and also enhance proliferation of those cells (Mahajan et al., 2007). 
Concerning the effect of phosphorylation on polyQ toxicity, blockade of serine 516 
phosphorylation (catalyzed by a mitogen-activated protein kinase - MAPK) was found 
to abrogate polyQ expanded AR-induced cell death and formation of caspase-3-
derived cleavage products, which is a key event in SBMA pathogenesis (LaFevre-Bernt 
& Ellerby, 2003). Interestingly, however, phosphorylation of both serines 426 and 516 
appear to have opposite effects, depending on the size of the polyQ sequence: 
blockade of these modifications, while diminishing expanded protein toxicity, turns non-
expanded AR into a cytotoxic agent (Funderburk et al., 2008). Mimicking 
phosphorylation of serines 215 and 792, appointed as targets of Akt, by substitution 
with aspartate residues reduces AR ligand binding, ligand-dependent nuclear 
translocation, transcriptional activation and toxicity of the expanded form; co-
expression of Akt had similar effects and blocked expanded AR-induced cell death 
(Palazzolo et al., 2007). Recently Akt phosphorylation of AR was further demonstrated 
to reduce its aggregation and increase its degradation by the UPP and Akt activation 
was shown to reduce the disease phenotype of a SBMA mouse model (Palazzolo et 
al., 2009). 
 Attending to all these results, phosphorylation of polyQ-containing proteins 
appears to have the two possible opposite effects concerning pathogenesis: it can 
either be protective or contribute to the pathological mechanisms and cell loss, 
depending on the protein involved and the phosphorylated site(s) in question. This is in 
accordance with the importance and ubiquitous nature of phosphorylation as a 
regulating effect. One can expect phosphorylation to be a PTM whose effect varies 
greatly between different diseases, as its effect depends on the protein it is modifying. 
 As of this date, few work has been done in order to understand the importance 
phosporylation has on atx3 properties and so as to establish whether (and how) it 
affects the mechanisms underlying MJD. 
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Through biochemical analysis of the phosphoamino acids present on 32
Importantly, there are already some clues to the possible biological relevance of 
these modifications. Mimicking phosphorylation of serine residues 236, 340 and 352 
leads to an increased nuclear localization of atx3 in a way independent from the NLS 
described, and to an enhanced repression of atx3-regulated transcription (Evert et al., 
2006a; Macedo-Ribeiro et al., 2009; Mueller et al., 2009). “Phosphorylation” of residues 
340 and 352 also correlated with increased stability and half-life (Mueller et al., 2009). 
Casein kinase 2 (CK2) was shown to interact with atx3 and phosphorylate its UIM-
containing C-terminal region (Mueller et al., 2009; Tao et al., 2008). CK2 
pharmacological inhibition reduced atx3 levels in the nucleus and NI formation and 
activated atx3-regulated gene transcription, indicating that CK2-dependent 
phosphorylation (either directly or indirectly) regulates these properties, probably by 
interference with the phosporylated state of the above three residues (Mueller et al., 
2006). Concurrent mutation of every phosphorylation site does not result in any 
differences concerning atx3 molecular interactions (p97/VCP, Rad23B and HDAC3 
were specifically tested), though simultaneous mutation of the phosphorylation sites 
present in the second UIM to aspartates increased the minimum size of the polyUb 
chains that are bound by the protein.  
P-
orthophosphate-radiolabled samples of atx3, Mueller and co-workers (Mueller et al., 
2009) recently showed that, apparently, atx3 is phosphorylated only on serine residues, 
as the authors were unable to detect the presence of neither phosphothreonines nor 
phosphotyrosines. In fact, the reports currently available have only mapped serine 
phosphorylation sites, all belonging to the UIMs: serine 236, located on the first UIM, 
serines 256 and 260/261 (it is not clear which of the adjacent serine residues is 
phosphorylated), located on the second UIM, and serines 340 and 352 of the third UIM 
(present only in some atx3 isoforms) (Fei et al., 2007; Mueller et al., 2009). 
Some of the few available studies report that normal and expanded forms of 
atx3 are phosphorylated at similar levels, but there are some hypotheses that try to 
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explain possible links between phosphorylation and expanded atx3 toxicity (Mueller et 
al., 2009; Trottier et al., 1998). Phosphorylation of serines 236, 340 and 352 may 
participate in the nuclear translocation of expanded atx3 and, in the nucleus, the 
phosphorylated protein may lead to aberrant atx3-regulated gene expression (Evert et 
al., 2006a; Mueller et al., 2009). The increased stability may contribute to increased 
aggregation and NI formation. In fact, C-terminal-containing fragments of atx3 showed 
an increase of NI formation when serines 340 and 352 were mutated to mimic 
phosphorylation (Mueller et al., 2009). Furthermore, stress stimuli also induced atx3 
nuclear translocation in a CK2-dependent manner, pointing out a mechanism through 
which proteotoxic stress may potentiate the expanded protein nuclear localization. Fei 
and co-workers (Fei et al., 2007) reported that serine 256 is phosphorylated by 
glycogen synthase kinase 3 β (GSK 3β), but observed a decreased phosphorylation of 
the expanded form of the protein. Contrary to those observations indicating a possible 
nefarious effect for atx3 phosphorylation, these authors observed that preventing 
phosphorylation of serine 256 in an expanded form of atx3, but not of a normal form of 
the protein, enhanced its aggregation ability. These results indicate that there may be 
some relation between the serine 256 phosphorylation and the formation of the toxic 
protein aggregates. Hsp70, a molecular chaperon that promotes protein folding and 
has a protective effect against polyQ diseases (Muchowski & Wacker, 2005), was able 
to disrupt aggregation of the non-phosphorylated expanded atx3, further evidencing 
that non-phosphorylated expanded atx3 is prone to form aggregates. As stated before, 
the effect of phosphorylation can be predicted to differ according to the different 
residues modified, thus conciliating these apparent conflicting observations. 
More work will be necessary in order to increase our understanding of atx3 
phosphorylation and of its role in the pathogenesis of MJD. A better conception of the 
biological roles of normal atx3 and the possible changes introduced by the polyQ 
expansion, as well as of the effects of phosphorylation in those contexts, will be 
needed. Importantly, phosphorylation has been described as one of the mechanisms 
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by which DUBs are regulated and the majority of these enzymes has already been 
demonstrated to be phosphorylated in vivo. Phosphorylation of DUBs may either 
increase or decrease their protease activity and there are many studies showing that 
this modification influences DUBs physiological roles in the overall cellular context 
(Nijman et al., 2005; Reyes-Turcu et al., 2009).  
 
1.4.3 – Sumoylation of polyglutamine disease proteins 
 
 Sumoylation is a reversible PTM that shares many characteristics with 
ubiquitination and that has been recently shown to be widespread among the proteins 
of the cell. Like ubiquitination, it consists in the covalent attachment of a small protein, 
in this case small Ub-like modifiers (SUMO), to one or several lysine residues of 
another protein. As of yet, four SUMO proteins have been identified: SUMO1, 2, 3 and 
4. The very cycle of sumoylation has a lot of common aspects with ubiquitination, with 
the enzymes involved in sumoylation, also named E1, E2 and E3, acting mainly in the 
same way as the ones involved in that other PTM. That is to say, the E1 activating 
enzyme (a heterodimer of SUMO1-activating enzyme subunit 1 - SAE1 - and SAE2) 
binds and activates SUMO through an ATP-dependent reaction, and the protein is then 
transferred to the E2 conjugating enzyme, which, together with a E3 ligase (there are 
several described), transfers it to the target lysine residue of the substrate protein, 
forming an isopeptide bond between them. However, contrary to ubiquitination, the E2 
conjugating enzyme (termed Ub-conjugating enzyme 9 - Ubc9) has the ability to both 
recognize the target lysine residue and catalyze the transference of the SUMO protein 
by itself; E3 ligases mainly increase the efficiency of the process and help in 
determining the substrate specificity, being unnecessary in some of the cases (Anckar 
& Sistonen, 2007; Dorval & Fraser, 2007; Zhao, 2007). Sumoylation is highly specific in 
terms of the lysine residues to which SUMO is conjugated, not sharing with 
ubiquitination its certain degree of promiscuity when selecting the residues for 
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modification (Anckar & Sistonen, 2007). Again, similarly to ubiquitination, the 
constitution of polySUMO chains is possible, too (Dorval & Fraser, 2007). Removal of 
SUMO is termed desumoylation and is catalyzed by desumoylases, which are 
equivalent to (and sometimes considered as) DUBs (Reyes-Turcu et al., 2009). 
Unlike ubiquitination, however, sumoylation is not associated with the targeting 
of proteins for degradation. So far, sumolylation has been implicated in changes in the 
substrate protein’s function, activity, stability, subcellular localization, molecular 
interactions and susceptibility for other PTM processes, (Zhao, 2007). However, all of 
these vast changes can mainly be traced back to the modulation of molecular 
interactions, appointed as the primary effect of sumoylation (Geiss-Friedlander & 
Melchior, 2007; Zhao, 2007). 
The role of sumoylation in these cellular activities has been shown to be 
significant in many disease contexts (Dorval & Fraser, 2007). Moreover, the relation 
between ubiquitination and sumoylation doesn’t end in the similarities between the two 
processes; in fact, some of the target lysines are the same for both PTMs, suggesting 
the existence of a dynamic interplay between them (Dorval & Fraser, 2007; Wilson & 
Heaton, 2008). Taking all this into account, sumoylation must be considered a 
candidate for an important role regarding regulation of atx3 properties and MJD 
pathogenesis. 
Several authors have associated sumoylation with numerous 
neurodegenerative disorders and a few studies have already tried to associate this 
PTM with polyQ expansion diseases (Figure 6). So far, SUMO proteins have been 
detected in the typical cellular inclusions seen in many neurodegenerative diseases 
and have been shown to target some of the proteins linked to their pathogenesis 
(Terashima et al., 2002; Steffan et al., 2004; Dorval & Fraser, 2007). 
Neurons in affected regions of the brain of patients of HD, SCA1, DRPLA and 
MJD were shown to have a high immunoreactivity for SUMO-1 (Ueda et al., 2002). In 
the cerebellar cortex of MJD patients, Purkinje cells displayed granule-like signals in 
Introduction 
48 
 
 
Figure 6 – Sumoylation effects on polyQ toxicity. (A) Sumoylation can 
directly alter transcriptional activity of the mutant polyQ protein (1) or 
promote sequestration of transcription factors/regulators (2). (B) Sumoylation 
can change subcellular localization, possibly affecting transcription (3) and/or 
formation of inclusions (4). (C) SUMO modification may also antagonize 
proteasome-mediated degradation of the mutant polyQ protein, possibly 
leading to protein accumulation, sequestration of other proteins and 
formation of inclusions. These toxic effects may contribute to cell loss in 
polyQ expansion diseases. (Adapted from Dorval & Frasier, 2007) 
the cytoplasm while granule cells had a homogenous signal in the nucleus. 
Interestingly, although no definite co-localization between Ub (often observed in the NIs 
of MJD) and SUMO-1 was observed in any cell type, a positive correlation between 
their signals was detected in Purkinje cells (Ub stain in the nucleus was greater in high 
SUMO-1-signal cells), while in granule cells the relation was the opposite (Pountney et 
al., 2003). Though the SUMO-1 signal may also be related to proteins other than atx3 
that also contribute to pathogenesis, this study revealed a cell-specific relationship 
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between ubiquitination and sumoylation, that may be relevant for the processes 
involved in MJD development. 
Other authors reported the presence of SUMO-1 in the neuronal NIs of DRPLA 
patients’ brain tissues and cells expressing expanded atrophin-1, showing an 
enhanced sumoylation of expanded atrophin-1-induced aggregates (Terashima et al., 
2002). Additionally, abrogation of sumoylation in cells expressing expanded atrophin-1, 
through the co-expression of a sumoylation-defective SUMO-1 mutant, reduced 
aggregate formation and cell death, comparing with the co-expression of wild-type 
SUMO-1. These results seem to indicate a possible positive correlation between 
sumoylatation and disease.  
Studies show that SUMO-1 is conjugated to lysines 386 and 520 of the AR and 
that this modification somehow interferes with its transcriptional activity (Poukka et al., 
2000; Kaikkonen et al., 2009). Additionally, sumoylation appears to occur in a ligand-
induced manner and SUMO-specific proteases 1 and 2 (SNP-1 and -2, respectively) 
are able to reverse the modification (Kaikkonen et al., 2009). Regarding the importance 
of sumoylation in SBMA pathogenesis, studies made in Drosophila expressing a 
fragment of an expanded form of the human AR reported that the normal degeneration 
caused by this protein is enhanced by the compromise of SUMO-1 conjugation 
(achieved by co-expressing an inactive form of an E1 enzyme). Such situation led to a 
degeneration phenotype very similar to the one resulting from the inhibition of the 
proteasome system or the molecular chaperon Hsp70. Moreover, although Hsp70 was 
able to rescue the disease phenotype caused by inhibition of the proteasome, that was 
not the case in respect to the inhibition of the E1 (Chan et al., 2002). Importantly, the 
same authors reportedly obtained similar results with a MJD model expressing 
expanded atx3. Together, these results suggest that sumoylation protective effect may 
be partly related with protein aggregation. A recent study went as far as demonstrating 
that enhanced sumoylation (apparently of the AR itself) in fact reduces polyQ 
expanded AR aggregation (Mukherjee et al., 2009).  
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The results of the two studies cited above demonstrate that sumoylation may be 
associated with the development and consequences of DRPLA, SBMA and MJD, the 
main focus of the present work. Although sumoylation occurrence seems to precipitate 
pathology of DRPLA, while somehow having a protective effect in SBMA and MJD, it 
should be considered that these studies refer to a general modification of sumoylation, 
at the level of the whole cell, and not only of the protein of interest. Thus, the most 
important aspect to be considered is that sumoylation seems to be important for the 
pathological mechanisms of these diseases. It is of great relevance to try to understand 
the effects of sumoylation of the disease protein itself. 
Animal models expressing an expanded form of ataxin-1 have increased levels 
of sumoylated proteins in the cerebellar cortex (Ueda et al., 2002), though a later work 
showed that expanded ataxin-1 had a decreased sumoylation, when compared to the 
non-expanded form (Riley et al., 2005). It was also reported, however, that there are 
several factors influencing ataxin-1 sumoylation: inhibition of serine 776 
phosphorylation restored sumoylation, showing a possible interplay between these two 
PTMs, and a functional nuclear localization signal is necessary for the occurrence of 
that same modification. 
Sumoylation of a fragment of huntingtin in vitro was shown to increase its 
stability and accumulation, decrease its aggregation and enhance transcription 
repression (transcription repression is a deleterious effect observed in many polyQ 
diseases, including HD) (Steffan et al., 2004). The authors of this work also suggested 
that attachment of SUMO proteins to the expanded huntingtin could mask a 
cytoplasmic retention signal, targeting the protein to the nucleus, and that differences 
of such event between different cell types may explain the selective neuronal loss. 
Furthermore, experiments with a Drosophila animal model revealed that sumoylation of 
the disease protein enhances cell death. This may appear to be contradictory to the 
fact that it decreases aggregate formation, but this decreased aggregation can also 
indicate an increased amount of toxic soluble oligomers (this explanation was also 
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used to elucidate why phosporylation of threonine 3, while having a protective effect, 
enhances aggregation; Aiken et al., 2009). Researchers also showed that the effect of 
sumoylation is not only a result of a blockade of ubiquitination, a PTM that appears to 
be protective in this case. If that was the case, mutation of the target lysines would 
produce cytotoxicity; instead, cytotoxicity decreased, showing that the modification of 
these residues by sumoylation is more significant to pathogenesis (Steffan et al., 
2004).  
To this date, atx3 has never been shown to be sumoylated and, apart from what 
has been said above, no one has ever properly dealt with its possible influence in MJD. 
There are many ways by which sumoylation may contribute to the pathogenesis of this 
disease, though these potential mechanisms are just theoretical models suggested by 
what has been seen for other polyQ diseases. Through competition or disruption, 
sumoylation may block atx3 degradation by the proteasome system, leading to protein 
aggregation and inclusion formation; taking into account its importance as modulator of 
intermolecular interactions, sumoylation may also contribute to the sequestration of 
other molecules to the aggregates (Dorval & Fraser, 2007; Terashima et al., 2002; 
Ueda, et al., 2002). Given its role in the subcellular protein targeting, and in particular in 
nucleo-cytoplasmic shuttling, SUMO modification may also lead to the nuclear 
transport of atx3, which, in turn, leads to an increased formation of nuclear aggregates. 
The formation of aggregates and NIs and subsequent SUMO-mediated recruitment of 
important cellular systems may contribute to deleterious effects such as transcriptional 
changes. Another possibility may be the contribution of sumoylation to the formation of 
the toxic oligomers appointed to be decisively important (Dorval & Fraser, 2007; 
Steffan et al., 2004; Terashima et al., 2002).  
Nonetheless, considering what was seen above, inhibition of sumoylation 
appears to have a negative effect, contributing to degeneration in a MJD model (Chan 
et al., 2002). These results could lead to the suspicion that, in fact, sumoylation has a 
protective role in MJD, but even though sumoylation seems to prevent some damage in 
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the work cited, one cannot conclude that this is due to sumoylation of atx3. The 
experiments were done trough a general disruption of sumoylation, which may have 
interfered with other cellular systems, aggravating the degeneration. 
Further work directed to atx3 in particular must be done in order to establish if 
the protein is sumoylated, and in what conditions does this modification happen. It will 
then be important to determine if sumoylation, like phosphorylation and ubiquitination, 
is responsible for the regulation of atx3 properties, and evaluate how it interferes with 
the pathogenesis of MJD. Similarly to ubiquitination and phosphorylation, DUB activity 
has been shown to be regulated by sumoylation (Reyes-Turcu et al., 2009). For 
example, Ub-specific protease 25 (Usp25) was shown to be sumoylated in its two UIMs 
and such modification impaired binding to and hydrolysis of Ub chains (Meulmeester et 
al., 2008). 
 
1.5 – Objectives  
 
Considering what is currently known about regulation of DUB activity and 
pathogenesis of polyQ expansion diseases, further study into atx3 PTMs may be of key 
importance in increasing our understanding of the presently elusive function of this 
protein, and at the same time provide relevant clues concerning MJD pathogenesis. 
Consequently, the main aim of this experimental work was to try and describe novel 
PTMs of atx3 whose putative biological relevance may be later assessed, this way 
contributing to our comprehension of atx3 properties. Of all the existing possibilities, we 
directed our focus at two particular PTMs, phosphorylation and sumoylation, since they 
are known modulators of DUB function and polyQ toxicity (Reyes-Turcu et al., 2009). 
Phosphorylation is likely to also target amino acids other than the ones already 
described as being phosphorylated (and to different effects) and sumoylation has never 
been described to directly modify atx3. Accordingly, our objectives were to map new 
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phosphorylation sites of atx3 and determine whether this protein conjugates with 
SUMO. 
Since previous studies concerning atx3 phosphorylation primarily focused on 
serine phosphorylation, we started by trying to detect tyrosine phosphorylation using a 
phospho-specific antibody. Then, in order to straightforwardly map phosphorylation 
sites, we used a mass spectrometry (MS) approach that allows the precise detection of 
phosphorylated residues. This kind of strategy already yielded comprehensive 
information regarding huntingtin and AR (Guo et al., 2006; Schilling et al., 2007). 
Protein samples used in these studies were to be obtained from human cell lines, since 
they are more likely to reflect what physiologically happens in cells within the human 
organism. 
In order to try and determine if atx3 is a target for SUMO conjugation, we 
performed in vitro sumoylation assays on recombinant atx3 JD purified from bacteria. 
Then, with the intention of assessing the relevance of our in vitro results in the proper 
cell context, these assays were followed by cotransfection experiments performed on 
human cell lines. 
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2.1 – Materials 
 
Dulbecco’s Modified Eagle Medium (D-MEM), Minimum Essential Medium 
(MEM), protease inhibitors chymostatin, pepstatin, antipain and leupeptin (CLAP) and 
brilliant blue R were acquired from Sigma-Aldrich Química S.A. (Sintra, Portugal). Fetal 
bovine serum (FBS), MEM Non-Essential Amino Acids (NEAA), geneticin G-418 
sulphate, trypsin and Opti-MEM® were obtained from Gibco, as part of Invitrogen Life 
Technologies (Barcelone, Spain). LipofectamineTM Reagent was purchased from 
Invitrogen Life Technologies (Barcelone, Spain). Phorbol 12-myrisate 13 acetate (PMA) 
and in vitro SUMOylation kit were acquired from Biomol, as part of Enzo Life Sciences 
(Lausen, Switzerland). Triton X-100 and bovine serum albumin (BSA) were purchased 
from Calbiochem, as part of Merck KGaA (Darmstadt, Germany). Pierce® BCA Protein 
Assay Kit was obtained from Thermo Scientific (Rockford, USA). Protein A Sepharose 
CL-4B, Enhanced Chemifluorecense substrate (ECFTM) and Hiprep 26/60 were 
acquired from GE Healthcare (Carnaxide, Portugal). Low protein binding centrifugal 
filters (0,45 μ) were purchased from VWR (Carnaxide, Portugal). HisTrap HP column 
was purchased from Amersham Biosciences (Carnaxide, Portugal). Sodium dodecyl 
sulfate (SDS), SDS-polyacrilamide gel electrophoresis (SDS-PAGE) buffer (10x 
Tris/Glycine/SDS stock), acrylamide/Bis and acrylamide solutions were acquired from 
Bio-Rad (Amadora, Portugal). Page blue stain was obtained from Fermentas, 
distributed by Bioportugal (Porto, Portugal). Polyvinylidene difluoride (PVDF) 
membranes were obtained from Millipore (Madrid, Spain). QuikChange® II XL Site-
Directed Mutagenesis Kit was purchased from Stratagene (Cambridge, UK). Primers 
MJD1a-K166R_for and MJD1a-K166R_re were acquired from Bonsai Technology 
(Linda-a-Velha, Portugal); primers atx31_1n_S12D_for and atx31_1n_S12D_rev were 
purchased from Bonsai Technology, as part Fisher Scientific (Loures, Portugal). 
QIAprep® Spin Miniprep Kit and QIAGEN Plasmid Mini Kit were obtained from QIAGEN 
(QIAGEN GmbH, Hilden, Germany). All other reagents were obtained from Carlo Erba 
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Reagents (Rodano, Italy), José M. Vaz Pereira, S.A. (Benavente, Portugal), PanReac 
Química S.A.U. (Barcelona, Spain), Sigma-Aldrich (Sintra, Portugal) and Merck 
(Darmstadt, Germany). 
All solutions were aqueous, expect for those of phenylmethanesulphonyl 
fluoride (PMSF) and PMA, which were prepared in dimethyl sulfoxide (DMSO). 
 
2.2 – Expression plasmids 
 
Eukaryotic expression pEGFP plasmid encoding human atx3 variant 1a (NCBI 
accession number: AAB33571.1) with 28 glutamines (GFP-atx3-Q28
Bacterial expression pDEST17 plasmids encoding 6His-tagged human atx3 
variant 1-1n (6His-atx3; NCBI accession numbers: NP_004984.2) and 6His-tagged JD 
(6His-JD) have been previously described by our group (Gales et al., 2005). 
) fused with green 
fluorescent protein (GFP) in the N-terminal was a kind gift from Dr. Henry Paulson, 
University of Iowa (Iowa City, USA; plasmids described in Chai et al., 1999b). pcDNA3 
plasmids expressing hexahistidine (6His)-tagged human SUMO isoforms 1, 2 and 3 
(6His-SUMO1 and 6His-SUMO2, respectively) were a kind offer from Dr. Paul E. 
Fraser, University of Toronto (Toronto, Canada; described in Dorval & Fraser, 2006 
and sequenced for confirmation). 
 
2.3 – Antibodies 
 
Anti-GFP monoclonal antibody (mice) was acquired from Roche Applied 
Science (Carnaxide, Portugal). Anti-6His polyclonal antibody (rabbit) and anti-
phosphotyrosine monoclonal antibody (mice) were purchased from Cell Signalling 
Technology (Boston, USA). Anti-SUMO2/3 polyclonal antibody (rabbit) accompanied 
the SUMOylation kit acquired from Biomol, as part of Enzo Life Sciences (Lausen, 
Switzerland). Alkalyne phosphatase-conjugated anti-mouse and anti-rabbit 
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immunoglobulin G (IgG) secondary antibodies were obtained from GE Healthcare 
(Carnaxide, Portugal). Pre-immune rabbit IgG was purchased from Santa Cruz 
Biotechnology (Santa Cruz, USA). 
 
2.4 – Protein sequence and structure analysis 
 
Human atx3 variant 1a putative phosphorylation sites and kinases were 
determined by analysis of its amino acid sequence (NCBI accession number: 
AAB33571.1) using two phosphorylation prediction web-based softwares: Scansite 2.0 
(http://scansite.mit.edu/) and NetPhosK 1.0 
(http://www.cbs.dtu.dk/services/NetPhosK/). Prediction of possible sumoylation targets 
was made online using the SUMOplotTM
JD tertiary structure was obtained from the RCSB Protein Data Bank 
(http://www.pdb.org; Protein Data Bank - PDB - ID code 1YZB) and structural analysis 
was performed using the PyMOL Molecular Graphics System software (DeLano 
Scientific, San Carlos, USA). 
 Analysis Program 
(http://www.abgent.com/tools/sumoplot; Abgent, San Diego, California).  
 
2.5 – Mammalian cell culture and transfection 
 
Human embryonic kidney (HEK) 293FT cells were grown in D-MEM, 
supplemented with 10% (v/v) FBS, 0,1 mM NEAA, 6 mM L-glutamine, 1mM sodium 
syruvate (in MEM) and 500 μg/ml geneticin. Cells were maintained at 37 ºC, in a 
humidified atmosphere containing 5% CO2
One day prior to transfection, fully confluent HEK 293FT cells were diluted 1:6 
and then seeded onto 10 cm diameter culture plates. After 24 h of growth, transient 
transfection was carried out using Lipofectamine reagent with a modified version of the 
manufacturer’s protocol, as follows: after substituting the culture medium for 6,4 ml 
. 
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Opti-MEM supplemented with 10% FBS, lipid-DNA complexes obtained by mixing 10 
μg of DNA plasmid with 6 μl of Lipofectamine reagent in 800 ml Opti-MEM were added 
to each cell plate; after overnight incubation under normal growth conditions, 
transfection medium was replaced for normal HEK 293FT cell medium and expression 
was left to occur for 24 h of cell growth. In the case of co-transfections, lipid-DNA 
complexes were generated using 10 μg of each desired plasmid. 
 
2.6 – Chemical stimuli 
 
Some transfected HEK 293FT cell cultures were subjected to chemical 
stimulation directed at enhancing phosphorylation with 20 nM OA for 16 h (Dorval & 
Fraser, 2006), 5 mM sodium orthovanadate (Na3VO4
 
) for 30 min (Martin et al., 2006) 
or 200 nM PMA for 20 min (following the recommended of the manufacturer). All 
concentrations are final. These treatments were carried out in the final 24 h of cell 
culture, immediately before cell harvesting, at 37 ºC. 
2.7 – Immunoprecipitation 
 
Transfected HEK 293FT cell cultures were briefly washed with cold phosphate 
buffer saline (PBS; 137 mM NaCl, 2,7 KCl, 1,8 mM K2PO4, 10 mM Na2HPO4·H2O, pH 
7,4) and whole cell extracts were then prepared by adding 600 μl of IP buffer (IPB; 20 
mM Tris pH 7,0, 100 mM NaCl, 2 mM EDTA, 2 mM EGTA, 50 mM NaF, 1 mM Na3VO4) 
supplemented with 1% Triton X-100, 1 μM OA and protease inhibitors (1 mM DTT, 0,1 
mM PMSF, 10 μg/ml CLAP) and scraping on ice. After being sonicated on a probe 
sonicator for 1 min, lysates were cleared of their insoluble fraction by centrifugation 
(13.200xg, 10 min, 4 ºC) and protein concentration was assessed by the bicinchoninic 
acid (BCA) method using the BCA protein kit, according to the recommendations of the 
manufacturer. Input samples were prepared by mixing the extracts with 2x 
Materials and Methods 
 
61 
 
concentrated SDS-PAGE sample buffer (125 mM Tris pH 6,8, 100mM glycine, 40% 
glycerol, 4% SDS, 200 mM DTT, 0,01% bromophenol blue) and boiling at 95 ºC for 5 
min. 
One mg of protein from each extract (diluted to 1 mg/ml, with the same buffer) 
was pre-cleared by incubation with 50 μl of a slurry of Protein A Sepharose beads (1:1 
in IPB) for 1 h, followed by riddance of the beads by centrifugation (13.200xg, 5 min). 
Samples were then incubated overnight with 3 μg of anti-GFP or anti-phosphotyrosine 
antibody and precipitation of the immunocomplexes was performed by incubation with 
100 μl of the Protein A Sepharose slurry for 2 h 30 min. The beads were then washed 
by centrifugation (13.200xg, 1 min), 2 times with IPB plus 1% Triton X-100, 3 times with 
IPB containing 500 mM NaCl and 1% Triton X-100 and 2 times with IPB. The above 
procedures were all carried out at 4ºC. Elution was finally achieved by adding 50 μl of 
2x concentrated SDS-PAGE sample buffer to the beads, boiling at 95 ºC for 5 min and 
spinning with centrifugal filters (13.000xg, 5 min). Resulting samples and inputs were 
analyzed by Western blot. IP control was made using pre-immune IgG instead of 
antibodies. 
For MS analysis, 3 samples of each extract were subjected to this IP procedure, 
but collectively eluted in sequence by adding 2x concentrated SDS-PAGE sample 
buffer to the beads of one samples, boiling, spinning, adding the resulting eluent to 
another sample’s beads and starting the procedure again. 
 
2.8 – Heat shock stimulus and immobilized metal ion affinity 
chromatography 
  
In the final 1 h of cell growth, some of the transfected HEK 293FT cell cultures 
cells were submitted to a heat shock stimulus, by transferring the respective plates to a 
42 ºC hot bath. Control cells were kept at 37 ºC. Cultures were then momentarily 
washed with cold PBS and whole cell extracts were prepared by scrapping the plates in 
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600 μl of immobilized metal ion affinity chromatography (IMAC) buffer (8 M urea, 100 
mM NaH2PO4
One mg of protein from each extract (diluted to 1 mg/ml, with the same buffer) 
was incubated for 2 h with 50 μl of a slurry of Ni Sepharose beads (1:1 in IMAC buffer 
containing 20 mM imidazole). The beads were then washed by centrifugation 
(13.200xg, 1 min, 4 ºC) once with IMAC buffer containing 10mM imidazole and twice 
with 10 mM imidazole IMAC buffer, pH 6,4, in order to remove any nonspecifically-
bound proteins. Until this point, every procedure was performed at 4ºC. Elution was 
finally performed by adding 50 μl of IMAC buffer containing 500 mM imidazole, pH 6,4, 
to the beads, incubating for 3 min and spinning with centrifugal filters (13.000xg, 5 
min). After denaturation with SDS-PAGE sample buffer and boiling, resulting samples 
and inputs were analyzed by Western blot. 
 pH 8, 10 mM iodoacetamide, 10 mM β-mercaptoethanol, 1% Triton X-
100, 5 mM imidazole) containing 100 μg/ml DTT, 0,1 mM PMSF, 10 μg/ml CLAP and 1 
μM OA, on ice. Cells were sonicated on a probe sonicator for 30 s and the insoluble 
fraction of the lysates was then disposed of by centrifugation (13.200xg, 10 min, 4 ºC). 
Protein concentration was assessed by the BCA method using the BCA protein kit, 
according to the recommendations of the manufacturer. Input samples were prepared 
by mixing the extracts with 2x concentrated SDS-PAGE sample buffer and boiling at 95 
ºC for 5 min. 
 
2.9 – Bacterial expression and purification of recombinant proteins 
 
Escherichia coli BL21(DE3)-SI cells (Invitrogen Life Technologies, Barcelone, 
Spain) were transformed with the pDEST17 plasmids encoding 6His-atx3 and 6His-JD 
through heat shock. Cells were grown at 37 ºC in NaCl-free Luria broth medium (10% 
(w/v) triptone, 5% (w/v) yeast extract) with 100 μg/l ampicillin and 0,2% (w/v) glucose 
until the optical density (absorbance at 600 nm) reached 0,4-0,8, at which point 
expression was induced through addition of NaCl to a final concentration of 300 mM. 
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Expression was left to occur for 3 h, at 30 ºC. The cells were then collected by 
centrifugation (10.500xg, 20 min, 4ºC) and ressuspended in imidazole buffer (20 mM 
sodium phosphate pH 7,5, 0,5 M NaCl, 10 mM imidazole) containing lysozyme and 
kept at -20 °C. Before purification, serine protease inhibitor PMSF was added to a final 
concentration of 1 mM and the cells extracts were digested with 5 μg/ml DNAse I (in 
the presence of 10 mM MgCl2
The resulting supernatant was applied to a 5 ml HisTrap HP column (Amersham 
Biosciences, Carnaxide, Portugal) and eluted by rise of the imidazole concentration in 
three steps, through addition of imidazole buffer containing 50 mM, 100 mM and 500M 
imidazole. SDS-PAGE (12,5% (v/v) bis-acrylamide) followed by Page blue staining 
were carried out in order to determine which fractions were suitable for further 
purification, considering their enrichment in the protein of interest.  
) for 1 h, in ice, after which the samples were cleared of 
their insoluble fraction by centrifugation (17.400xg, 40 min, 4ºC). 
Appropriate fractions were pooled and then loaded to a Hiprep 26/60 (GE 
Healthcare; Carnaxide, Portugal) equilibrated in buffer A (20 mM HEPES pH 7,5, 200 
mM NaCl, 1 mM DTT, 1 mM EDTA, 5% (v/v) glycerol). Elution was carried out at 4 ºC 
with a flow rate of 0,5 ml/min and resulting fractions were analysed by SDS-PAGE 
followed by Page blue staining. The purest fractions were pooled and concentrated. 
Afterwards, samples were immediately frozen in liquid nitrogen and stored at -80ºC. 
Protein concentration was assessed by measurement of the absorbance at 280 nm 
using extinction coefficients of 36,160 M-1cm-1 and 34,760 M-1cm-1
 
, for 6His-atx3 and 
6His-JD, respectively. 
2.10 – In vitro sumoylation assays 
 
In vitro sumoylation assays were based on Biomol’s SUMOylation Kit, using a 
modified version of the recommended procedure. 200 nM 6His-JD was incubated for 1 
h, at 37 ºC, with SUMO E1, SUMO E2 and 6His-conjugated SUMO isoform 2 (6His-
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SUMO2-aa), in the presence of Mg-ATP, 20 units/ml inorganic pyrophosphate (iPP), 
1,5 mM DTT and the suitable reaction buffer (final reaction volume of 20 μl). Enzymes, 
6His-SUMO2-aa, reaction buffer and Mg-ATP were supplied by the kit and added as 
recommended by the manufacturer. The 6His-SUMO2-aa designation is used in order 
to distinguish the kit-supplyed SUMO2 protein construct from the 6His-SUMO2 we 
expressed in HEK 293FT cells.  
Positive controls were made replacing 6His-JD for Ras-related nuclear protein 
GTPase activating protein 1 (RanGAP1; Saitoh & Hinchey, 2000) according to the 
standard procedure. Negative controls were made excluding Mg-ATP and iPP. After 
incubation, reactions were stopped by quenching the assays with 2x concentrated 
SDS-PAGE loading buffer and denaturating by heating to 65 ºC for 5 min. Resulting 
samples were analysed by Western blot. 
 
2.11 – SDS-PAGE and Western blot 
 
Samples destined for Western blot analysis were electrophoresed in 
polyacrilamide gels until a suitable separation of the molecular weight standards was 
achieved. Depending on the situation, we used either a MiniPROTEAN® 3 system or a 
larger, PROTEN® II xi, system (Bio-Rad, Amadora, Portugal), that allowed loading of 
larger sample volumes; usage of this system is specified in the figure legends. Gel bis-
acrylamide concentration was 10% (v/v) when using the first system and 7,5% (v/v) 
when using the other one. Loaded volumes of each input were determined so that the 
applied protein mass was the same for each lane of a single electrophoresis (40-90 
μg); immunoprecipitant or IMAC-purificated samples’ quantity was made constant by 
applying 20 μl of each of them, in the case of the MiniPROTEAN® 3 system, or the total 
obtained volume, in the case of the PROTEN® II xi system. Proteins were then electro-
transferred (40 V) overnight, at 4 ºC, to PVDF membranes. 
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In the case of the samples resulting from the in vitro sumolylation assays, we 
electrophoresed 10 μl of each in 12,5% ((v/v) bis-acrylamide) gels (MiniPROTEAN®
 Membranes were blocked by 1 h incubation with Tris-buffered saline (20 mM 
Tris-HCl, 137 mM NaCl, pH 7,6) containing 0,1% (v/v) Tween 20 (TBS-T) and 5% (w/v) 
low-fat dry milk. Incubation with primary antibodies diluted as recommended in TBS-T 
containing 0,5% (w/v) low-fat dry milk was carried out according to the manufacturer’s 
instructions: anti-GFP and anti-SUMO2/3 antibodies were diluted 1:1.000 and 
incubated for 1 h at room temperature, while the anti-6His antibody, also diluted 
1:1.000, was overnight at 4 ºC. Membranes were then washed with TBS-T containing 
0,5% (w/v) low-fat dry milk (5 times, 5 min each) and subsequent incubation with 
suitable alkaline phosphatase-conjugated secondary antibody diluted 1:20.000 in the 
above solution was performed for 1 h at room temperature. Membranes were again 
washed and then resolved using ECF. Scanning was performed using Storm 860 Gel 
and Blot Imaging System (Amersham Biosciences, Buckinghamshire, UK). In the case 
of the anti-phosphotyrosine antibody (diluted 1:2.000 and incubated overnight at 4ºC), 
milk was substituted for 5% (w/v) BSA and washing was performed using TBS-T, in 
every step of the procedure. When reprobing was intended, membranes were stripped 
with 0,2 M NaOH for ~10 min and again blocked and marked as described. 
 3 
system) and performed the electrotransference for 3 h and using nitrocellulose 
membranes instead. 
 
2.12 – Mass spectrometry 
 
For MS analysis, triple immunoprecipitants (~100-150μl) were alkylated by 
incubation with 1% (v/v) acrylamide for 20 min, at room temperature, and their protein 
content was separated by SDS-PAGE in 7,5% polyacrylamide gels using the 
PROTEAN® II xi system (100 μl of each was loaded into the gel). Gel fixation and 
staining were performed simultaneously by incubation with 45% (v/v) methanol, 10% 
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(v/v) acetic acid, 0,25% (w/v) Coomassie brilliant blue R for 8 min, and followed by 
destaining with 25% methanol, 5% acetic acid. In order to minimize possible 
contaminations with keratin, these solutions were prepared anew and every material 
contacting with the gel was washed with 1% SDS and mQ water. Polyacrilamide gel 
bands containing GFP-atx3 were excised using a clean scalpel, covered in mQ water 
and frozen.  
Online liquid chromatography (LC) followed by ion spray MS (LC-ES-MS) 
analysis of the bands of interest was performed by the Proteomics Center at Children’s 
Hospital Boston (Boston, USA). Gel-contained protein samples were subjected to an 
in-gel digestion with 12,5 ng/μl sequencing-grade trypsin (Promega, Madison, USA) in 
100mM ammonium bicarbonate, overnight, at 37ºC, after which the resulting peptides 
were extracted with 100mM ammonium bicarbonate and acetonitrile and lyophilized. 
Samples were ressuspended in 5% acetonitrile, 5% formic acid and then directly 
injected into a LC/MS system encompassing a micro-autosampler, a Suvery HPLC 
pump and a Proteome X (LTQ) mass spectrometer (all acquired from Thermo Finnigan, 
San Jose, USA). The LC system featured a reversed phase column, packed in-house 
using C18 Magic packing material (3 mm, 200 Å; Michrom Bioresources, Auburn, 
USA), and PicoTip Emitters (New Objective, Woburn, USA). In the LC/MS system, 
peptides were eluted with 0,1% formic acid in acetronitrile, using a 30 min linear 
gradient of 8% to 34% acetonitrile, and then applied to the mass spectrometer by 
electrospray ionization. MS spectra were acquired by the Proteome X (LTQ) mass 
spectrometer in a data-dependent fashion, with the 6 top abundant species being 
selected for automated fragmentation. Phosphorylated peptides were detected by the 
characteristic mass shift of 80 or 98 m/z that corresponds to the neutral loss of a 
phosphate group. When the fragmentation of a MS spectrum resulted in an immediate 
neutral loss mimicking this mass shift in the MS2, then a MS3 fragmentation was 
performed on the resulting MS2 peak. The mass spectrometric data obtained was 
searched against the human international protein index database (IPI human 336) 
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using the protein identification software Mascot (version 2.2.04; Matrix Sciences, 
London, UK) according to the appropriate search criteria necessary for the detection of 
phosphorylation.  Spectra sequence identified by Mascot to be phosphorylated were 
validated manually to guarantee proper recognition of phospharylated amino acid 
position and to access overall quality of the data obtained. 
 
2.13 – Site-directed mutagenesis 
 
Mutagenesis was performed using the QuikChange II XL Site-Directed 
Mutagenesis Kit (Stratagene, Cambridge, UK), according to the procedure suggested 
by the manufacturer. Mutant 6His-atx3 S12D, with serine at amino acid residue 12 
substituted for aspartate, was generated from the pDEST17 6His-atx3 DNA template 
using primers atx31_1n_S12D_for (5’-CAC GAG AAA CAA GAA GGC GAC CTT TGT 
GCT CAA CAT TGC CTG-3’) and atx31_1n_S12D_rev (5’-CAG GCA ATG TTG AGC 
ACA AAG GTC GCC TTC TTG TTT CTC GTG-3’). Mutants 6His-atx3 K166R and 
6His-JD K166R, with lysine at amino acid residue 166 substituted for arginine, were 
generated from the pDEST17 plasmids encoding 6His-atx3 and 6His-JD, respectively, 
using primers MJD1a-K166R_for (5’-GGT TAT TCT ATA TTT GTT GTT AGG GGT 
GAT CTG CCA GAT TGC G-3’) and MJD1a-K166R_rev (5’- CGC AAT CTG GCA GAT 
CAC CCC TAA CAA CAA ATA TAG AAT AAC C-3’). Mutation of the expression 
plasmids was confirmed by automatic sequencing (STAB VIDA, Oeiras, Portugal).  
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3.1 – Phosphorylation 
 
3.1.1 – Amino acid sequence analysis of human ataxin-3 reveals 18 
putative phosphorylation sites 
 
As described above (see section 1.4.2), the only amino acid residues that are 
possibly subjected to phosphorylation are serines, threonines and tyrosines. Different 
kinases target residues according to the particular amino acid sequence in which they 
are inserted, and, taking into account the characteristics of these sequence motifs, it is 
possible to make a rough prediction of the potential phosphorylation sites of a protein, 
through an analysis of its primary sequence. Our analysis of the amino acid sequence 
of the human atx3 variant 1a (AAB33571.1) revealed 18 putative phosphorylation sites: 
8 serines (S12, S29, S35, S256, S260, S265, S321 and S347), 5 threonines (T122, 
T138, T269, T274, T277) and 5 tyrosines (Y27, Y58, Y99, Y147 and Y160) (Table III). 
Some of these amino acids were revealed as possible targets of more than one kinase. 
As mentioned above, serines 256 and 260/261 have already been shown to be 
phophorylated (Fei et al., 2007; Mueller et al. 2009); serine 256 was however targeted 
by glycogen synthase kinase 3 β (GSK3β), an enzyme different than the one predicted 
(in the case of serine 260/261 it is not very clear whether it is phosphorylated by CK2). 
Importantly, serines 340 and 352, also described to be phosphorylated (Mueller et al. 
2009), belong to the third UIM and are thus absent from this atx3 variant. 
These prediction data allows the establishment of a starting point for the study 
of atx3 phosphorylation, considering that it points out a limited number of sequences 
whose characteristics make certain amino acids eligible for phosphorylation by various 
kinases. However, it should be noted that this is just a rough indication based on the 
protein primary sequence, hence experiments are necessary to determine which of the 
putative residues are actually modified. 
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Table III – Putative phosphorylation sites of human atx3 variant 1a (as 
predicted by Scansite 2.0; see Obenauer et al., 2003) 
Amino acid 
residue Sequence Score 
Prediction  
percentile 
Surface 
accessibility Kinase 
Basophilic serine/threonine kinase group (Baso_ST_kin) 
S12 FHEKQEGSLCAQHCL 0,5329 4,786 % 0,235 PKCδ 
T122 NYKEHWFTVRKLGKQ 0,4902 1,305 % 0,875 PKCα/β/γ 
S256 LRRAIQLSMQGSSRN 0,4901 1,971 % 0,744 PKCδ 
S260 IQLSMQGSSRNISQD 0,5514 4,175 % 2,307 PKCα/β/γ 
S265 QGSSRNISQDMTQTS 0,6980 3,310 % 1,029 Akt 
S265 QGSSRNISQDMTQTS 0,4923 0,550 % 1,029 CaMK2 
S321 QQQQRDLSGQSSHPC 0,7189 4,131 % 0,971 Akt 
DNA damage kinase group (DNA_dam_kin) 
S265 QGSSRNISQDMTQTS 0,5021 0,542 % 1,029 DNA PK 
S265 QGSSRNISQDMTQTS 0,6252 4,260 % 1,029 ATM 
T269 RNISQDMTQTSGTNL 0,5730 1,868 % 1,831 ATM 
T269 RNISQDMTQTSGTNL 0,6078 2,840 % 1,831 DNA PK 
T277 QTSGTNLTSEELRKR 0,6308 4,632 % 1,831 ATM 
Acidophilic serine/threonine kinase group (Acid_ST_kin) 
S35 FSPVELSSIAHQLDE 0,6555 4,297 % 0,327 GSK3 
T274 DMTQTSGTNLTSEEL 0,5018 3,275 % 0,872 CK1 
Proline-dependent serine/threonine kinase group (Pro_ST_kin) 
S29 LLQGEYFSPVELSSI 0,6750 4,405 % 0,828 Cdc2 
T138 FNLNSLLTGPELISD 0,6615 4,279 % 0,596 Erk1 
S347 SDLGKACSPFIMFAT 0,6750 4,405 % 0,156 Cdc2 
Tyrosine kinase group (Y_kin) 
Y27 NNLLQGEYFSPVELS 0,4998 3,292 % 1,104 EGFR 
Y58 GGVTSEDYRTFLQQP 0,4927 3,745 % 2,542 PDGFR 
Y58 GGVTSEDYRTFLQQP 0,7197 3,821 % 2,542 IR 
Y99 ILFNSPEYQRLRIDP 0,5101 3,952 % 2,690 EGFR 
Y147 PELISDTYLALFLAQ 0,5325 4,489 % 0,595 Fgr 
Y160 AQLQQEGYSIFVVKG 0,7244 4,099 % 0,501 IR 
 
Score (0,0000-1,0000) represents the degree to which the sequence identifies with the quantified kinase 
preferences for each different amino acids in a motif, while percentile (0,000-100,000%) indicates the 
fraction of top fits in which the sequence is included, when compared to all the records of Vertebrate 
proteins from the Swiss-Prot database. So, in general terms, the predicted probability of a certain amino 
acid being phosphorylated increases with the increase of the score and the decrease of the percentile. 
Surface accessibility is calculated solely basing on the amino acid sequence. Bolded amino acid symbols 
represent the phosphorylation target of each sequence. The light blue shading signals the name of the 
different kinases groups analyzed, while the grey shading indicates sites that have already been described 
as being phosphorylated (Fei et al. 2007, Mueller et al., 2009). Kinase name abbreviations: PKC, protein 
kinase C; CaMK2, calmodullin-dependent kinase 2; DNA PK, DNA-dependent protein kinase; ATM, ataxia 
telangiectasia mutated kinase; GSK3, glycogen synthase kinase 3; CK1, casein kinase 1; Cdc2, cell 
division cycle 2 kinase; Erk1, extracellular signal-regulated kinase 1; EGFR, epidermal growth factor 
receptor kinase; PDGFR, platelet-derived growth factor receptor kinase; IR, insulin receptor kinase; Fgr, 
Gardner-Rasheed feline sarcoma viral oncogene homolog kinase. 
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3.1.2 – GFP-atx3 expression and purification 
 
It was our goal to try and detect atx3 phosphorylation sites in purified protein 
samples obtained from a human cell line, since these expression conditions are much 
more likely to better reflect what happens in actual human cells, as far as post-
translational processing of atx3 is concerned. This procedure doesn’t allow for such a 
large scale of protein purification as other methods do, but, in fact, bacteria, though 
yielding large amounts of recombinant proteins, do not perform PTMs, and even for 
eukaryotic organisms, the more evolutionarily apart they are, the more unlikely are they 
to process their proteins in the same way – thus, using eukaryotic cell lines other than 
human is still not sufficient. Detection of phosphorylation in proteins derived from 
human cells gives a much stronger indication that the observed modification is 
biologically relevant. Additionally, since we aimed at detecting atx3 phosphorylation 
sites using MS techniques specially directed to the study of this PTM, two other main 
goals had to be reached: a) to obtain highly pure proteins samples, since any impurity 
might hinder or interfere with the extremely sensible MS analysis; b) to obtain a large 
protein quantity, so as to allow for the analysis of the greatest number of peptides 
possible (see section 3.1.4 for more details on this).  
We thus expressed GFP-atx3 in HEK 239FT cells and purified it by IP using a 
monoclonal anti-GFP antibody. Evaluation of the efficacy of the procedure was done by 
Western blot analysis, through observation of the enrichment of the protein of interest 
in the inputs (both soluble and insoluble fractions) and the immunoprecipitant (Figure 
7).  
GFP-atx3 expression was highly effective, considering that a clear ~75 KDa 
band was detected in the transfected cells soluble input sample, but not in the non-
transfected control (~75 KDa is the molecular mass expected for this fusion protein). 
Furthermore, the small amount of GFP-atx3 present in the insoluble fraction of the 
transfected cells (considering that the electrophoresed sample corresponds to 10x the 
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Figure 7 – Expression and IP of GFP-atx3. HEK 293FT cells were 
transiently transfected with GFP-atx3 and expression was left to occur for 24 
h. The protein was purified by IP using a monoclonal anti-GFP antibody and 
a slurry of protein A Sepharose beads, and the resulting immunoprecipitant 
samples, along with the soluble and insoluble fractions of the input, were 
analyzed by Western Blot with the anti-GFP antibody. Observation of the 
GFP-atx3 signal in the input samples indicates that expression and 
solubilization of the protein were successfully achieved; the GFP-atx3 band 
present in the immunoprecipitant attests for the efficacy of the IP procedure. 
Relative protein amount contained in each electrophoresed sample is 
represented in brackets as a percentage of the total starting protein mass 
subjected to IP. NT refers to the non-transfected cells controls. 
protein mass of the soluble inputs) indicates that our procedure efficiently solubilized 
GFP-atx3. 
Analysis of the immunoprecipitants content revealed that GFP-atx3 IP was 
successfully achieved. Purity of the IP samples is further attested by the absence of 
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Figure 8 – GFP-atx3 SDS-PAGE protein bands subjected to MS 
analysis. HEK 293FT cells were transiently transfected with GFP-atx3 and 
expression was left to occur for 24 h, during which time period cells were 
stimulated with Na3VO4, PMA or OA, as described. GFP-atx3 was then 
purified by IP using a monoclonal anti-GFP antibody and a slurry of protein A 
Sepharose beads. The protein content of the immunoprecipitants was 
separated by SDS-PAGE (using a PROTEAN® II xi system) and the resulting 
gel was stained with Coomassie blue. Asterisk (*) represents bands 
subjected to MS analysis. Empty vector encoding GFP was used as negative 
control. 
any significative protein bands in Coomassie stained SDS-PAGE gels, other than IgG 
chains and GFP-atx3 itself (Figure 8). As detailed above (see section 2.7), the amount 
of purified GFP-atx3 that was intended to be analyzed by MS was increased by 
triplicating the total protein mass that was subjected to IP, with no parallel increase of 
the final immunoprecipitant volume. 
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3.1.3 – Probing with a phosphotyrosine-specific antibody 
 
To this date, though there are several tyrosine residues in atx3 putatively 
targeted for phosphorylation, studies so far have mainly focused on serine/threonine 
phosphorylation. Moreover, in their most recent work, Mueller and collaborators (2009) 
could not detect phosphotyrosines in the phosphoamino acid analysis of atx3. 
As a first approach to determining the actual relevance of tyrosine 
phosphorylation in atx3, before MS experiments, we analyzed some IP-purified GFP-
atx3 samples obtained from transfected HEK 293FT by Western blot with an anti-
phosphotyrosine antibody (Figure 9). In order to enhance protein phosphorylation, cells 
were also stimulated with one of two phosphatase inhibitors, OA or Na3VO4 (which 
inhibit serine/threonine or tyrosine phosphatases, respectively), or the protein kinase C 
(PKC) stimulator PMA (selected for the fact that many putative phosphorylation sites 
are targeted by PKC). OA and PMA served as negative controls for the expected 
Na3VO4-enhanced tyrosine phosphorylation. Though the anti-phosphotyrosine 
antibody labeling revealed a protein band that seems to correspond to GFP-atx3 
(Figure 10B), possibly indicating that the protein is phosphorylated in tyrosine residues 
under our experimental conditions, the labeling is in fact very weak and the Na3VO4
 In order to clarify this situation, we also tried the reverse experiment, 
immunoprecipitating the tyrosine-phosphorylated proteins from transfected HEK 293FT 
cells stimulated with Na
 
stimulus doesn’t seem to significantly increase the signal we observed. 
3VO4 using the anti-phosphotyrosine antibody and then seeing 
if we could detect GFP-atx3 in the immunoprecipitants (Figure 10). Though we were 
able to detect GFP-atx3 using this procedure, we also immunoprecipitated the protein 
with the pre-immune IgG control, which keeps us from being able to elaborate any 
conclusion about GFP-atx3 phosphorylation in tyrosines. This unspecific reaction may 
be due to the “sticky” nature of atx3, whose properties tend to make it aggregate with 
other molecules. Interestingly, however, the band we believe to correspond to GFP-
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Figure 9 – Western blot analysis of GFP-atx3 with an anti-
phosphotyrosine antibody. GFP-atx3 was expressed in HEK 293FT cells 
for 24 h, during which time period cells were stimulated with Na3VO4, PMA or 
OA, as described. (A) Input tyrosine-phosphorylated protein content was 
analyzed through Western with a monoclonal anti-phosphotyrosine antibody, 
yielding an indistinguishable smear. Samples resulting from IP with a 
monoclonal anti-GFP antibody were probed with both the (B) anti-
phosphotyrosine antibody and the (C) anti-GFP antibody. The phospho-
specific antibody revealed a very weak protein band that might correspond to 
GFP-atx3. 
atx3 seems to be a little heavier than usual in the samples immunoprecipitated with the 
phospho-specific antibody, specially comparing to the pre-immune IgG control. The 
shift in the mobility of GFP-atx3 could eventually be due to the attachment of one (or 
more) phosphate group(s), supporting the idea of tyrosine phosphorylation of GFP-
atx3. 
Taken together, our observations do not allow us to formulate any decisive 
conclusion about tyrosine phosphorylation of atx3. Considering what has been 
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Figure 10 – IP of GFP-atx3 using an anti-phosphotyrosine antibody. 
GFP-atx3 was expressed in HEK 293FT cells for 24 h. After being stimulated 
with Na3VO4 as described, cells were harvested and then tyrosine-
phosphorylated proteins were immunoprecipitated using a monoclonal anti-
phosphotyrsorine antibody and a slurry of protein A Sepharose. The 
resulting immunoprecipitants were electrophoresed (in a PROTEAN® II xi 
system) and probed for the presence of GFP-atx3 with a monoclonal anti-
GFP antibody. IP control was made by replacement of the anti-
phosphotyrosine antibody with pre-immune IgGs. GFP-atx3 is present in 
both the anti-phosphotyrosine antibody immunoprecipitants and the negative 
controls, making any conclusion regarding GFP-atx3 tyrosine 
phosphorylation unfeasible. 
previously observed by Mueller et al. (2009), we believe that this lack of clear evidence 
for tyrosine phosphorylation in our experiments may be indicative of low levels of 
tyrosine phosphorylation of atx3 (if they any at all). 
  
3.1.4 – Mass spectrometric analysis of GFP-atx3 detects phosphorylation 
of serine 12 
 
During the past years, MS has turned into a well-established method for the 
detection and identification of phosphorylated peptides, allowing the direct mapping of 
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particular phosphorylated amino acid residues (Macek et al., 2009). Notably, previous 
studies concerning other polyQ expansion diseases proteins (in particular huntingtin 
and the AR) have successfully employed MS in their search for phosphorylation sites 
(Gioeli et al., 2006; Guo et al., 2006; Schilling et al., 2007). The main principle behind 
the procedure is the fact that the attachment of a phosphate group alters the molecular 
mass/charge ratio of a peptide, a change that can be detected by the mass 
spectrometer. In one particular strategy, when phosphopeptides are subjected to 
molecular fragmentation during the MS procedure, they may release free phosphate 
groups. The mass spectrometer is able to detect this neutral loss of a phosphate group 
(which corresponds to a mass shift of 80 or 98 m/z) and at the same time identify the 
peptides, based on the time of flight of the several fragments produced (Macek et al., 
2009). Analyzing the data altogether makes the exact mapping of phosphorylated sites 
possible. 
Therefore, in conformity with our main objective, in order to straightforwardly 
identify phosphorylated residues in GFP-atx3, we subjected the protein to that kind of 
mass spectrometric analysis, using a LC-ES-MS system (as detailed in section 2.9 – 
MS analysis). For this analysis we used IP-purified GFP-atx3 obtained from HEK 
293FT cells stimulated with OA, Na3VO4
Using this experimental approach, we were able to identify one phosphorylated 
peptide in the GFP-atx3 sample resulting from the OA-stimulated cells – 
Q
, or PMA, brought into play with the objective 
of enhancing possible protein phosphorylation. After separating the immunoprecipitant 
content by SDS-PAGE (Figure 8), GFP-atx3 protein bands were subjected to a tryptic 
digestion and the resulting peptides were thus processed and analyzed by the MS 
system for detection of phosphate group-yielding peptides and respective amino acid 
sequence identification. 
9EGpS12LCAQHCLNNLLQGEYFSPVELSSIAHQLDEEER45 – determining that serine 
12 is phosphorylated in GFP-atx3, under our experimental conditions (Figure 11). 
These results constitute strong evidence for serine 12 being a novel phosphorylation 
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Figure 11 – LC-ES-MS detection of serine 12 phosphorylation in GFP-
atx3. An IP-purified GFP-atx3 sample obtained from transfected HEK 239FT 
cells stimulated with OA was subjected to mass spectrometric analysis 
directed for the detection of phosphorylated peptides. (A) One 
monophosphorylated peptide was detected and the phosphorylation site 
mapped to the serine residue in position 12. (B) Human at3 variant 1a 
aminoacid sequence is represented with the peptides covered by the MS 
analysis colored in red. 
site of atx3. Additionally, as our starting GFP-atx3 protein sample was obtained from 
cells stimulated with a serine/threonine phosphatase inhibitor, OA, and no other 
artificial stimuli, we admit that phosphorylation of serine 12 may happen natively under 
the cell culture conditions we used, with the phosphatase inhibition only eventually 
increasing the fraction of phosphorylated protein. This indicates that serine 12 
phosphorylation may happen normally in cells and thus may have some kind of 
biological relevance. 
Other GFP-atx3 samples didn’t, however, yield any detectable phosphorylated 
peptides, and detection of the peptide referred above was somewhat weak, too. MS is 
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a technique for the detection of peptides, but because of the nature of the procedures 
and principles involded, only a fraction of the peptides of a sample may be expected to 
be detected. Therefore, the absence of detection must not be taken to mean that a 
named peptide (modified or not) does not exist in the starting sample; the only 
conclusion one must take is that detection was unsuccessful. In MS experiments, the 
more the protein amount analyzed, the better the peptide detection and the higher the 
percentage of amino acid sequence coverage. Additionally, it should be considered 
that only a relatively small fraction of a given protein shall be expected to be 
phosphorylated; this, coupled with possible dephosphorylation events during the IP 
procedure and an insufficiently high sample protein amount may explain the lack of 
detection of any additional phosphorylated peptides. This may also account for the lack 
of detection of peptides containing phosphorylated residues (serines 236, 256 and 
260/261) already described by other authors (Fei et al., 2007; Mueller et al., 2009). 
Everything considered, though subsequent experiments will be necessary to 
confirm our results (see section 4.2), MS analysis of GFP-atx3 was able to detect a 
new phosphorylation site of atx3, serine 12. The way we performed our experiments 
also points out for this modification to happen normally in cells. 
Our observations contrast in part with the results obtained from Mueller et al. 
(2009), who were unable to detect phosphorylation of the N-terminal of atx3 using 32P-
orthophosphate-labeled atx3 fragments. Seeing as both studies were made using HEK 
293 cells, this lack of detection by Mueller and coworkers may be due to low levels of 
serine 12 phosporylation in their samples (insufficiently high for the radio-labeling 
detection), comparing with our OA-stimulated samples. The strong signal they detected 
in the C-terminal region was conceivably due to the combination of the radioactive 
signals from the several phosphorylated sites present in the UIMs; notably, however, 
mutation of all these residues did not completely abolish full-length atx3 
phosphorylation signal, indicating that other phosphorylated residues might be present. 
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On our part, stimulation of the cells with OA combined with the MS strategy presented 
above allowed us the detection of phosphorylated serine 12. 
The phosphorylated amino acid prediction referred above presented serine 12 
as being putatively phosphorylated by PKCδ (Table III). Using another bioinformatic 
tool for the comparison of human atx3 variant 1a amino acid sequence with the 
consensus sites usually selected by a number of different kinases, we were able to 
determine other kinases possibly involved in serine 12 phosphorylation (Table IV). Out 
of all the putative kinases, PKCδ (as predicted by Scansite) and PKA (predicted by 
NetPhosK) were the ones with higher theoretical probability of phosphorylating serine 
12. As it will be discussed later, however, since these predictions are based only on the 
amino acid sequence preferences of the several kinases covered by these methods, 
more experiments are necessary for determining the kinase(s) responsible for the 
modification of serine 12 (see section 4.2). 
 
Table IV – Kinases putatively responsible for the phosphorylation of 
serine 12 from human atx3 variant 1a (as predicted by NetPhosK 1.0; 
see Blom et al., 2004) 
Kinase Score 
Protein kinase A (PKA) 0,57 
DNA-dendent protein kinase (DNA PK) 0,48 
Cell division cycle 2 kinase (Cdc2) 0,46 
Glycogen synthase kinase 3 (GSK3) 0,46 
Calmodullin-dependent 
kinase 2 (CaMK2) 0,42 
Casein kinase 1 (CKI) 0,38 
Protein kinase C (PKC) 0,32 
 
Score values (0,00-1,00) define how well the amino acid sequence 
containing the phosphate-accepting residue conforms with the sequence 
preferences determined for each kinase. 
Results and Discussion 
 
83 
 
3.1.5 – Serine 12 localizes close to the catalytic site and is accessible at 
the surface of the Josephin domain 
 
 Analysis of atx3 primary structure reveals that serine 12 is localized in the JD, 
very close to the cysteine residue of the active site (C14), and glutamine 9, another 
residue that is important for the catalytic activity of the protein (Masino et al., 2003) 
(Figure 12). Moreover, observation of the tertiary structure of the JD (Nicastro et al., 
2005;) showed that serine 12 localizes not only very close to cysteine 14 and glutamine 
9, but is also in the proximity of the amino acid residues that, along with cysteine 14, 
make up the catalytic triad - histidine 119 and asparagines 134 (Mao et al., 2005; 
Nicastro et al., 2005) (Figure 13). The JD is mainly composed of two subdomains, a 
globular catalytic subdomain and a helical hairpin, with the catalytic site being localized 
in the cleft that exists in the region of contact between them. Importantly, the overall 
structure does not allow for but a very limited movement between the two subdomains. 
Taking into consideration the proximity of serine 12 to the amino acids of the active site 
and the fact that it is localized in the region of contact between the two subdomains of 
the JD, it is reasonable to speculate that linkage of a phosphate group to that serine 
 
Figure 12 – Serine 12 is localized in the JD, close to the cystein residue 
of the active site. (A) Human atx3 variant 1a domain structure is 
schematically represented with (B) the JD aminoacid sequence displayed in 
detail. The active site residues are colored in red and serine 12 in blue. 
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Figure 13 – Serine 12 localizes in the vicinity of the aminoacids of the 
active site. Tertiary structure of the JD of atx-3 (Nicastro et al., 2005; PDB 
ID code 1YZB) is represented as a ribbon diagram, with serine 12 (in blue) 
and the aminoacids of the active site (in red) displayed as ball-and-stick 
models. (A) Serine 12 localizes in the contact region between the two 
subdomains. The close distribution of the active site residues and serine 12 
is highlighted and detailed in (B). 
residue is likely to affect the proteolytic activity of the JD of atx3. The presence of a 
negatively-charged phosphate group conjugated with the serine 12 side chain may 
produce changes possibly affecting a) the catalytic site conformation, consequently 
changing its aptitude to cleave the isopeptide bonds existing between Ub molecules 
(whether increasing or decreasing it), b) the way the JD interacts with the substrate(s), 
and/or c) the access and alignment of the catalytic site to the isopeptide bonds to be 
cleaved. 
  In order to graphically observe the relative accessibility of the serine 12 residue 
to the kinase(s) possibly responsible for its phosphorylation, we looked at the JD 
surface and examined the location of that serine residue (Figure 14A). It is clear that 
when the JD is in its folded conformation, serine 12 localizes in the surface of the 
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Figure 14 – Serine 12 distributes at the surface of the JD. (A) Surface of 
the JD of atx-3 (Nicastro et al., 2005; PDB ID code 1YZB) is represented 
with serine 12 colored in blue. (B) Tertiary structure in the close vicinity of 
serine 12 is displayed as a ribbon diagram under the transparent surface, 
while the serine residue itself is represented as spheres. Arrow indicates the 
phospho-accepting hidroxyl group of serine 12 side chain. 
domain, with its hydroxyl group-containing side chain turned towards the solvent 
(Figure 14B). Serine 12 thus appears to be relatively accessible for the interaction with 
the enzyme(s) possibly catalyzing its phosphorylation and to the subsequent 
attachment of a phosphate group. 
 
3.2 – Sumoylation 
 
3.2.1 – Amino acid sequence analysis of human ataxin-3 reveals 4 putative 
sumoylation sites, three of them localized in the Josephin domain 
 
In line with what has been said above for the prediction of possible 
phosphorylation sites, we analyzed the primary structure of human atx3 variant 1a, this 
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time searching only for amino acid sequences that somehow conformed to one 
particular tetrapeptide motif usually found in sumoylation targets: Ψ-K-X-D/E, where Ψ 
is a hydrophobic residue, K is the lysine residue that conjugates with SUMO, X is any 
amino acid and D/E is an aspartate or glutamate residue. This motif is viewed as the 
main sumoylation target sequence, taking into consideration its frequency in 
sumoylation targets and the fact that it is directly recognized by Ubc9, the only E2 
enzyme of the SUMO conjugating pathway, being important in the positioning of this 
protein and the fine-tuning of substrate lysine specificity (Anckar & Sistonen, 2007). 
This search exposed 4 putative sumoylation sites: lysines 8, 125, 166 and 206, with 
lysine 166 presenting a very high associated score (Table V). Three of this putative 
sites (the exception being lysine 206) are contained in the JD, the catalytic domain of 
atx3 (amino acids 1-182; Masino et al., 2003); thus, it is plausible to think that, should 
any of them be an actual target for sumoylation, there could be some kind of regulatory 
function associated with their modification by SUMO. 
 
Table V: Putative sumoylation sites of human ataxin-3 variant 1a (as 
predicted by the SUMOplotTM Analysis Program) 
Amino acid residue Sequence/group Score 
K8    ESIFH EKQE GSLCA 0,50 
K125    HWFTV RKLG KQWFN 0,27 
K166    YSIFV VKGD LPDCE 0,93 
K206    KEQRV HKTD LERML 0,52 
 
Score values (0,00-1,00) represent the probability for the recognized 
sequences to be targeted by sumoylation considering the degree of amino 
acid conformity with the Ψ-K-X-D/E sumoylation motif. Bold indicates the 
residues belonging to the recognized sequences, while underscore signals 
the actual putative lysine residue. 
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It should be noted, however, that although sumoylation is highly lysine-specific, 
not all Ψ-K-X-D/E tetrapeptides are in fact modified by SUMO. It has been suggested 
that other determinants may play important roles in defining the targeted lysines, with 
negative charges (either resulting from the presence of negatively-charged amino acids 
or phosphorylated amino acids) downstream the consensus site being pointed as 
possible additional signals; a positively-charged patch existing in the Ubc9 enzyme 
appears to be of significant importance in regulating sumoylation mediated by this 
determinants (Anckar & Sistonen, 2007; Mohideen et al., 2009). Moreover, recent 
developments have identified many SUMO-modified proteins lacking any known 
consensus site, consubstantiating the idea that, though the Ψ-K-X-D/E motif is 
frequently found in sumoylated protein, other as of yet unknown mechanisms 
completely independent of this tetrapeptide and probably involving more than a linear 
peptide motif may be important in targeting lysine residues for sumoylation (Blomster et 
al., 2009).  As this prediction relies only on the comparison with the Ψ-K-X-D/E motif, it 
is excluding those other determinants and unknown factors regulating sumoylation. In 
accordance with what has been stated before, this kind of prediction is not sufficient to 
generate any conclusion regarding actual sumoylation of a particular lysine residue, but 
helps to direct the subsequent experiments, starting from the basis established by the 
protein sequence analysis tools. 
 
3.2.2 – 6His-JD conjugates with SUMO2 under in vitro sumoylation 
reaction conditions 
 
 In order to determine if atx3 is a target for SUMO conjugation, we started with 
an in vitro approach, by performing sumoylation assays with an in vitro sumoylation kit 
(SUMOylation kit, Biomol). For these experiments we used 6His-JD instead of full 
length 6His-atx3, for two main reasons: a) the majority of the putative sumoylation sites 
are localized in the JD and b) should sumoylation be detected we would know that the 
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catalityc domain is a target for this modification. Since it was our goal to use a highly 
concentrated protein sample and we wished the protein was not post-translationally 
modified to begin with, we produced recombinant 6His-JD in E. coli and purified it by a 
series of chromatographic techniques using a protocol established by our group (Gales 
et al., 2005). 
Previous results obtained from in vitro sumoylation assays performed by our 
group (Mazovec G. & Macedo-Ribeiro S., 2009, personal communication) suggested 
no significant involvement of SUMO1 and SUMO3, and so we focused our study on 
SUMO2 alone. We thus incubated 6His-JD with 6His-SUMO2-aa in the presence of 
SUMO E1 and SUMO E2 (Ubc2), under the optimal reaction conditions. Western blot 
analysis of the resulting samples with a anti-SUMO2/3 antibody revealed the presence 
of a protein species with a molecular weight of ~37 KDa, higher than 6His-SUMO2-aa 
molecular weight of ~16 KDa; considering that 6His-JD alone has ~24 KDa (Gales et 
al., 2005), it is plausible to admit that the observed band corresponds to 6His-JD 
conjugated with 6His-SUMO2-aa (Figure 15). After reprobing with an anti-6His 
antibody, a large amount of unconjugated 6His-JD was still observed and no 6His-JD 
band with that higher molecular weight was detected; we can thus admit that only a 
small fraction of the total 6His-JD seems to be sumoylated under these conditions. 
Interestingly enough, existing evidences state that the fraction of a certain protein 
targeted by sumoylation that is actually modified by this process is very low (Hay, 
2005). Since we observed only that single band corresponding to sumoylated 6His-JD, 
we admit that our procedure just produced monosumoylated 6His-JD. This antibody did 
not detect 6His-SUMO2-aa probably because it is not sensible enough to detect the 
small amounts of 6His-SUMO2-aa used in the assay; in fact, though the protein is 
tagged with 6His, the manufacturer recommends usage of the SUMO2/3-specific 
antibody. 
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Figure 15 – In vitro sumoylation of 6His-JD. Recombinant 6His-JD 
expressed in E. coli and purified through a series of chromatographic steps 
was incubated for 1 h, at 37ºC, with 6His-SUMO2-aa and SUMO enzymes 
E1 and E2. The resulting sample and respective controls were analyzed by 
Western blot with (A) a polyclonal anti-SUMO2/3 antibody and (B) a 
polyclonal anti-6His antibody, revealing a protein band of ~37 kDa that is 
likely to correspond to 6His-JD conjugated with 6His-SUMO2-aa (6His-JD-
6His-SUMO2-aa). This band is absent in the negative control, with no ATP 
supply. Positive control was made using RanGAP1, a protein known to be 
sumoylated (RanGAP1-6His-SUMO2-aa) (Saitoh & Hinchey, 2000). 
 
These results strongly suggest that the catalytic domain of atx3 may be 
modified by conjugation with SUMO2, constituting the first plain evidence for atx3 
sumoylation. 
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Out of the three major SUMO isoforms, SUMO2 and SUMO3 are the ones 
sharing the greater homology (~95%), with SUMO1 sequence identifying only by ~50% 
with those of the other two (Dorval & Fraser et al., 2007). Though these three isoforms 
may conjugate with the same substrates under certain conditions, SUMO1 and 
SUMO2/3 are functionally different, being regulated by the cells through different 
mechanisms (Dorval & Fraser, 2007; Saitoh & Hinchey, 2000). They are differently 
expressed depending on the cell type in question and display characteristic subcellular 
localizations; interestingly, SUMO2, like atx3, is found both in the cytoplasm and in the 
nucleus, though predominantly in the nucleus (Vertegaal et al., 2004). Importantly, a 
recent study showed that the majority of SUMO2 substrates’ function is related to 
nucleic acid biology (Blomster et al., 2009); modification of atx3 by SUMO2 and 
possibly the interactions it mediates may influence the protein’s role in transcription 
regulation. Moreover, seeing as atx3 nuclear localization is important in determining its 
toxicity (Bichelmeier et al., 2007), there can be some mechanisms through which 
SUMO2 conjugation with polyQ expanded atx3 in the nucleus influences the pathways 
leading to MJD. 
Tough we observed no polysumoylation, SUMO2 and SUMO3 have been 
frequently related with the formation of polySUMO chains, which is mediated by the Ψ-
K-X-D/E sumoylation motif they have (Dorval & Fraser, 2007; Vertegaal et al., 2004). 
Though there are no other reasons to speculate that atx3 is polysumoilated, it is also 
possible that our experimental conditions may not be enough for the constitution of 
polySUMO chains. What is more, though many recently unveiled SUMO2 substrates 
present the Ψ-K-X-D/E motif, a similar amount of protein lacked any known consensus 
sequence, keeping us from being able to anticipate which JD lysine(s) are more likely 
to conjugate with this SUMO isoform. Interestingly, recent evidences suggest that 
SUMO-2 targeting mechanism depends on the biological role of the particular substrate 
(Blomster et al., 2009). 
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Ubiquitination of the JD alone was shown to be sufficient to increase its catalytic 
activity (Todi et al. 2009). Considering the often observed interplay between 
sumoylation and ubiquitination, which sometimes includes the targeting of the same 
lysine residues by the two PTMs, it is plausible to hypothesize the existence of a 
putative mechanism for the regulation of atx3 activity, resulting from the interplay 
between JD ubiquitination and sumoylation. This interplay may also influence the 
protein stability, taking into account polyUb role in the UPP. 
Be as it may, considering that these in vitro observations rely on strictly 
controlled and optimized conditions, other experiments are required in order to 
understand the authentic relevance of atx3 sumoylation by SUMO2 in the actual 
cellular context. 
 
3.2.3 – Cotransfection experiments were inconclusive in determining 
whether ataxin-3 conjugates with SUMO2 in cells 
 
In order to try and detect SUMO conjugation with atx3 in mammalian cells, we 
immunoprecipitated GFP-atx3 from HEK 293FT cells expressing both GFP-atx3 and 
6His-SUMO proteins (6His-SUMO1, 2 and 3) with the anti-GFP antibody and analyzed 
the resulting samples for detection of 6His-SUMO by Western blot (Figure 16C, D). 
Although the probing with the anti-6His antibody yielded no detectable bands that might 
correspond to 6His-SUMO protein conjugated with GFP-atx3, it should be noted, 
however, that no bands corresponding to 6His-SUMO were observed in the inputs 
themselves (Figure 16A, B). This can be due to a very low expression of the His6-
SUMO proteins or be the result of low sumoylation levels, considering that normally, in 
cells, only a small fraction of a named protein is eventually sumoylated (Hay, 2005).  
 In order to concentrate the 6His-SUMO proteins and the proteins that 
conjugated with them in the cells, we tried a reverse approach, by purifying the 6His-
SUMO proteins using a Ni Sepharose resin (IMAC). This time, we also aimed at 
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Figure 16 – IP experiments with cells cotransfected with GFP-atx3 and 
6His-SUMO proteins. HEK 293FT cells were cotransfected with both GFP-
atx3 and one 6His-SUMO isoform (6His-SUMO1, 2 or 3) and expression was 
left to occur for 24 h. Inputs (A, B) and samples resulting from IP with a 
monoclonal anti-GFP antibody (C, D) were analyzed by Western blot with 
both the monoclonal anti-GFP antibody and a polyclonal anti-6His antibody. 
Expression of the 6His-SUMO constructs may not have been successful, 
taking into consideration that no clear band corresponding to 6His-SUMO 
proteins (~20 KDa; Dorval and Fraser, 2007) was observed in the inputs. 
increasing the sumoylation levels by submitting the cotransfected cells to a heat shock 
treatment (1h at 42 ºC), since it has been previously described that stress stimuli 
increase the attachment of SUMO2 to their target proteins (Blomster et al., 2009; 
Saitoh & Hinchey, 2000). Additionally, SUMO2 localizes predominantly in the nucleus 
(Vertegaal et al., 2004); taking that into consideration and seeing that heat stress 
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Figure 17 – IMAC purification of 6His-SUMO from cells cotransfected 
with GFP-atx3 and 6His-SUMO. HEK 293FT cells were cotransfected with 
both GFP-atx3 and 6His-SUMO isoforms 1 or 2 (6His-SUMO1 or 2) and 
expression was left to occur for 24 h. During the last 1 h of protein 
expression, cells were subjected to a heat shock stimulus (HS), through 
incubation at 42 ºC.  Inputs (A, B) and samples resulting from IMAC with Ni 
resin (C, D) were analyzed by Western blot with both a monoclonal anti-GFP 
antibody and a polyclonal anti-6His antibody (IMAC-purified samples were 
electrophoresed using a PROTEAN® II xi system). Expression of the 6His-
SUMO constructs was unsuccessful once again and purification procedure 
was flawed, since GFP-atx3 was found in the IMAC-purified samples 
transfected only with GFP-atx3. 
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increases atx3 nuclear distribution (Mueller et al., 2009), we thought this procedure 
could potentiate sumoylation of atx3 in particular. In these experiments we focused 
only on 6His-SUMO1 and 2, since we wanted to compare between the SUMO isoform 
we determined to conjugate with 6His-JD (SUMO2) and one SUMO isoform that is not 
involved in the modification of 6His-JD, under the in vitro reaction conditions (SUMO1) 
(Mazovec G. & S. Macedo-Ribeiro, personal communication). 
Western blot analysis of the samples resulting from the Ni resin purification 
(Figure 17C, D) showed bands corresponding to GFP-atx3 with the same molecular 
weight as free GFP-atx3, and their detection was also possible in the case of the 
samples resulting from transfection with GFP-atx3 alone. As such, we admit that our 
experimental procedure was not effective at the Ni Sepharose purification level, but 
apparently may have also been ineffective during the very expression of the 6His-
SUMO constructs, considering that, once again, we were unable to detect 6His-SUMO 
even in the inputs (Figure 17A, B). Once again, we cannot exclude the possibility of the 
sumoylation levels being very low under our experimental coditions; future studies shall 
also include a positive control, like RanGAP1, for instance, that will allow as to test this 
prospect (Saitoh & Hinchey, 2000). 
Taking these points into consideration, though we were unable to detect 
conjugation between GFP-atx3 and 6His-SUMO in HEK 293FT cells using these 
experimental approaches, we can’t rule out the possibility of atx3 being modified by 
SUMO in vivo. Further experiments will be necessary to correctly study the eventual 
conjugation between atx3 and SUMO in cells (see section 4.2).  
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4.1 – Conclusions 
 
 The main aim of the experimental work that has been presented here was to 
determine novel PTMs affecting atx3, the protein causatively involved in the 
development of MJD. PTMs affect a vast number of protein properties and may thus 
account for the regulation of atx3 localization, activity, stability and aggregation, 
possibly being important in the pathogenesis mechanisms of MJD. Throughout this 
work we focused mainly on two PTMs: phosphorylation and sumoylation. 
Through mass spectrometric analysis of GFP-atx3 produced in HEK 293FT 
cells, we were able to detect phosphorylation of serine 12, a residue that is located at 
the surface of the JD and may therefore be exposed to this PTM. Additionally, serine 
12 is in close proximity to the catalytic site (especially to cysteine 14), which leads us to 
speculate that addition of a phosphate group to this serine residue may somehow 
affect atx3 enzymatic activity, possibly constituting a regulatory mechanism of its 
biological function, in the overall cell context. 
In vitro sumoylation assays pointed out to the fact that 6His-JD may conjugate 
with SUMO2, constituting the first concrete experimental evidence for sumoylation of 
atx3. Nonetheless, we were unable to confirm these results in mammalian cell models.  
 
4.2 – Future perspectives 
   
Having described two PTMs of atx3 that had never been identified before and 
considering the importance attributed to these modifications regarding protein function 
and polyQ disease mechanisms, this experimental work opens up a number of 
interesting possibilities for the study of atx3 biology and, consequently, MJD 
pathogenesis. Nonetheless, before the effect of the PTMs can be determined, more 
research will be necessary in order to confirm the modifications we identified and 
understand what are the conditions under which they are observed. 
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As it has been said before, mass spectrometric detection of the phosphorylated 
peptide was somehow weak, and so, in order to confirm our result, we will have to 
repeat the experiences we made. Besides, it will be very important to confirm this 
modification using another experimental approach, for instance by looking at the 
incorporation of (32
In the case of sumoylation, we will have to confirm our observations with further 
in vitro assays. We may also try to use this assays in order to see if the C-terminal is 
also targeted by sumoylation. Then, it will be crucial to clearly determine whether this 
modification happens normally in the actual cellular context, because only this way will 
we be able to know if it is biologically relevant. With this objective in mind, we may try 
an immunocytochemistry approach, in order to compare the distribution of either 
endogenous or recombinant atx3 and SUMO2 in cells, and see if they co-localize. 
Actual confirmation of atx3 (or JD) modification by SUMO2 may be achieved after 
optimization of our cotransfection experiments but, considering that the attachment of 
SUMO is generally very low, it would be important to try to enhance sumoylation by 
cotransfecting the cells with enzymes involved in the sumoylation pathway (for 
instance, the SUMO E2 enzyme, Ubc9; Kim et al., 2006) and avoid desumoylation 
through employment of specific SUMO hidrolase inhibitors. The purification procedures 
shall also suffer modifications directed at maximizing their specificity and efficiency. 
The observation of the profile of sumoylated atx3 or JD obtained from cells may also 
allow the detection of species corresponding to poly- or multisumoylation (that is, with 
several SUMO molecules attached to different lysine residues). 
P)-ortophosphate in GFP-atx3, in cells, and see if mutation of serine 
12 reduces the radioactive signal (Fei et al., 2007; Mueller et al., 2009). Importantly, 
however, since we just tried to increase GFP-atx3 phosphophorylation by generic 
inhibition of the serine/threonine phosphatases, we are inclined to admit that this 
modification happens normally in cells. 
It will be essential to follow up our definite confirmation of the results with a 
deeper characterization of the PTMs. In this respect, it will be important to determine 
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which is the enzyme responsible for phosphorylation of serine 12. The putative kinase 
data presented above (Table III and IV) may help selecting the enzymes that are most 
likely to target the serine 12 residue and confirmation may be achieved by trying to 
phosphorylate atx3 in vitro through incubation with the suspected enzymes and radio-
labeled orthophosphate and seeing if the mutation of the serine residue reduces the 
radioactive signal (Fei et al., 2007; Mueller et al., 2009). 
In the case of sumoylation, it may be significant to determine to which 
residue(s) does SUMO2 binds. This identification may be done through in vitro assays 
or cotransfection experiments using mutants where some of the putative lysine are 
mutated to arginines and subsequent analysis of the result in order to see if the 
mutation actually reduces the sumoylated protein signal (Dorval & Fraser., 2006; 
Steffan et al., 2004). 
After the characterization of the PTMs detected by the present work, it will be 
essential to carry on their study by trying to evaluate and portray their actual biological 
importance, by determining the effect they have on atx3 properties, similarly to what 
has been done with other atx3 PTMs (Mueller et al., 2009; Todi et al., 2009). In this 
context, it will be crucial to have the protein in the desired modified state. As far as 
phosphorylation is concerned, we have already generated a phosphomimetic serine 12 
mutant, in which serine 12 of 6His-atx3 is replaced by an aspartate residue, which is 
similar to serine, but negatively-charged (6His-atx3 S12D). The characterization of the 
effect that serine 12 phosphorylation is predicted to have on atx3 enzymatic activity 
may then be assessed by performing in vitro activity assays and comparing the mutant 
atx3 performance with that of the wild-type protein. Usage of different substrates may 
allow different kinds of study: Ub fluorogenic substrates may help in establishing kinetic 
differences, since they permit a continuous product detection; differently-linked polyUb 
chains may help in understanding if there are any differences in Ub linkage type 
preference caused by serine 12 phosphorylation, comparing to what has been 
previously published (Winborn et al., 2008). Importantly, phosphorylation has also been 
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related with changes in atx3 subcellular localization (Mueller et al., 2009) and so, in 
order to determine if serine 12 is also implicated in the process, we may analyze 
differences in subcellular localization between GFP-atx3 and both phosphomimetic and 
phosphodead mutants (where phosporylation is impossible due to serine substitution 
by an alanine residue), through citochemistry or cell fractioning techniques. 
Immunocitochemistry or cell fractionating techniques coupled with raising of 
phosphospecifc antibodies recognizing phosphorylated serine 12 may help to 
determine the natively-modified protein distribution in neuronal cells. It will also be 
relevant to try to compare the phosphomimetic mutant transcriptional repressor activity 
with that of the wild-type atx3 and the phosphodead mutant; this kind of study may be 
done through reporter gene assays of the matrix metallopeptidase 2 (MMP-2), 
according to what has been previously described (Mueller et al., 2009). The effect of 
serine 12 phosphorylation on atx3 stability may be evaluated using thermal stability 
assays and its cellular turnover may be determined by pulse-chase experiments (Todi 
et al., 2009). Changes in molecular interactions may be investigated by comparing the 
ability to co-immunoprecipitate known atx3 interactors from cell extracts between wild-
type atx3 and both the phosphomimetic and phosphodead mutants (Mueller et al., 
2009).  
Concerning atx3 sumoylation, we may try to analyze SUMO2-modifyed atx3 (or 
JD) activity using sumoylated protein samples obtained from in vitro sumoylation 
assays and subsequent enrichment of the modified species through chromatographic 
techniques. Importantly, this has already been done for another DUB (Muelmeester et 
al., 2008). The SUMO2-conjugated protein may then be used for the in vitro activity 
assays presented above, in order to determine whether this modification, similarly to 
ubiquitination (Todi et al., 2009), affects atx3 enzymatic activity. Studies looking for 
possible differences in subcellular distribution, transcriptional repressor activity, 
turnover and protein-protein interaction may instead require transfection of the cells 
with atx3 recombinant proteins mimicking the SUMO2 modification. In previous studies 
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concerning polyQ disease proteins sumoylation, this has been done by generating 
fusion proteins containing both the polyQ tract-containing protein and SUMO2, fused in 
frame (Steffan et al., 2004). Alternatively, those experiments may be performed using 
atx3 SUMO conjugation-deficient mutants, obtained by substituting the lysine residues 
involved in SUMO conjugation for arginine residues. In this respect, we have already 
generated atx3 and JD mutants where lysine 166, the putative residue with the highest 
associated score, is replaced by an arginine (6His-atx3 K166R and 6His-JD K166R, 
respectively). 
The final step in the evaluation of the biological importance of serine 12 
phosphorylation and JD sumoylation will be to determine if these PTMs are somehow 
involved in the mechanisms underlying MJD. It will then be necessary to try and see if 
the ratio of phosphorylated or sumoylated protein differs from normal and expanded 
atx3 and compare the functional effects of the modifications between both normal and 
expanded protein. The observations may then be interpreted according to the 
mechanisms admittedly related with MJD pathogenesis. Considering what has been 
speculated about the possible involvement of PTMs with polyQ expansion diseases’ 
selective neurodegeneration profile (Pennuto et al., 2009), it will also be crucial to 
evaluate the distribution of the modified protein in the brain of animal models, and then 
see how the modified protein abundance overlaps or not with the brain regions that are 
reported to be dysfunctional in MJD. In the case of phosphorylation, this may be done 
using the phospho-specific antibodies referred above; as for sumoylation, Western blot 
comparison between different brain fractions is likely more appropriate. 
Important clues may also be provided by the effects these modifications have 
on atx3 tendency to aggregate. In cells, this may be assessed by immunocitochemistry, 
by observing the tendency of phosphomimetic and phosphodead mutants to form 
aggregates or inclusions, or by SDS-PAGE and Western blot, directed at the detection 
of high molecular weight species resulting from atx3 aggregation (Fei et al., 2007). In 
the case of sumoylation, experiments may be done using the SUMO2-atx3 fusion 
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protein or the SUMO conjugation-deficient mutants (Mukherjee et al., 2009; Steffan et 
al., 2004).  
Lastly, if any significant hypothesis arise from the previous observations, it will 
be important to understand the effects of these modifications in vivo. This may be done 
by generating animal models expressing phosphomimetic or phosphodead atx3 
proteins, both expanded and non-expanded, and determining if any differences can be 
observed regarding phenotype, cell death and inclusion formation, always comparing 
the results with the observations from non-modified atx3-expressing animals. 
Regarding sumoylation, these in vivo studies may be done using sumoylation-deficient 
atx3 mutants, as previously done with huntingtin (Steffan et al., 2004). 
Further understanding the biologic importance of the two PTMs described in the 
present work may prove relevant for the constitution of a solid body of knowledge 
regarding atx3 elusive function and the neurodegenerative disease it causes when its 
polyQ sequence is expanded. 
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